

Curriculum Vitae

Angela B. Smith, MD, MS, FACS
2115 Physician's Office Building
Chapel Hill, NC 27599-7235
919-962-5421 (phone)
919-966-0098 (fax)

EDUCATION

- 2014— American Board of Urology, Board Certified
ABU #18642
- 2012— North Carolina State Medical Board, Board Certified
Certificate #140997
- 2012—2014 MS in Clinical Research
University of North Carolina, School of Public Health
Chapel Hill, NC
- 2003—2007 MD
University of North Carolina School of Medicine
Chapel Hill, NC
- 1999—2003 BSPH in Biostatistics with Highest Honors
University of North Carolina at Chapel Hill
Chapel Hill, NC
- 1999—2003 BA in Music Performance with Highest Honors
University of North Carolina at Chapel Hill
Chapel Hill, NC

PROFESSIONAL EXPERIENCE

- 2020— Vice Chair of Academic Affairs
Department of Urology
University of North Carolina at Chapel Hill, School of Medicine
Chapel Hill, NC
- 2019— Director of Urologic Oncology
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill, School of Medicine
Chapel Hill, NC
- 2018— Associate Professor with Tenure
Department of Urology
University of North Carolina at Chapel Hill, School of Medicine
Chapel Hill, NC
- 2018—2022 Assistant Secretary for Latin America/Caribbean
American Urological Association,
Linthicum, MD

2012—2018 Assistant Professor
Department of Urology
University of North Carolina at Chapel Hill, School of Medicine
Chapel Hill, NC

2008—2012 Urologic Surgery Residency
University of North Carolina Hospitals
Chapel Hill, NC

2007—2008 General Surgery Internship
University of North Carolina Hospitals
Chapel Hill, NC

1999—2007 Biometric Consulting Laboratory, Research Assistant
Chapel Hill, NC

2000—2002 UNC Neurology Laboratory, Laboratory Assistant
Chapel Hill, NC

2001 GlaxoSmithKline, Biostatistics Research Assistant
Durham, NC

HONORS

- AUA Gold Cystoscope Award, 2022
American Urological Association Award for outstanding leadership and contributions in bladder outcomes research. Only one recipient is chosen for the award internationally each year.
- Yang Family Biomedical Scholars Award, 2021
Award includes \$75,000 to further research program recognized by nomination
- AUA Southeast Section Ambrose-Reed Award, 2021
Awarded to a urologist who represents a pioneer in the field of health policy and DEI
- Castle Connolly's Top Doctors, 2020, 2021
Awarded to national physicians who are nominated by peers at the highest level of training, clinical skills, professional appointments, research, leadership, professional reputation and interpersonal skills.
- Best Doctors Distinction, Best Doctors □ 2015—2021
- Castle Connolly's Exceptional Women in Medicine, 2020, 2021
Special acknowledgement based on outstanding accomplishments and dedication in the field of medicine.
- UNC Health Care and Faculty Physicians Award for Carolina Care Excellence, 2019, 2020
>95% of patients responded "Yes, definitely" when asked if they would recommend me to their friends
- UNC Hettleman Prize for Artistic & Scholarly Achievement, 2020
Awarded annually to four associate professors who exemplify groundbreaking and innovative research along with future career promise across the University of North Carolina campus
- AUA Young Urologist of the Year, 2020
Recognition of efforts & commitment to advancing development of fellow early-career urologists

- SUO Young Investigator Award, 2020
Recognition of excellence for the improvement of clinical care and progress in science
- National Institutes of Health Loan Repayment Program, 2013—2020
- Best of Bladder Cancer Advocacy Network Award 2019
Annual award given to advocates dedicated to bladder cancer advocacy
- *British Journal of Urology International* Article of the Week, “Impact of Bladder Cancer Diagnosis on Health-Related Quality of Life,” April 2018.
- NIH mHealth Training Institute, mHealth Scholar, 2017
Selected for a week-long immersion program to foster and sustain synergistic interactions and research networks and actualize transdisciplinary mHealth solutions
- Jefferson-Pilot Fellowship in Academic Medicine, 2017
Four-year \$20,000 award given to promising junior faculty at the UNC School of Medicine
- BJU International Social Media Awards, *Journal of Urology* awarded “Best Journal” as Assistant Editor for Online Content, 2017
- Junior Faculty Development Award – University of North Carolina, 2016
- *British Journal of Urology International* Coffey-Krane Prize (for best paper in citations, quality and potential impact on practice), Trainee: David Johnson, 2016
- *Journal of Urology*, Best Reviewer 2013, 2014
- Selected for Mentorship by American College of Surgeons Women Mentorship Program, 2014
- *British Journal of Urology International* Article of the Week, Video Feature, August 2014
- Research Fellowship (1 year), Surgical Outcomes Club, 2013
- UNC Urology Resident Scholar Award, 2012 (highest percentile on Urology in-service exam)
- UNC Lineberger Clinical Fellows Award for Research Excellence, 2012
- NIH-National Medical Association Travel Award for Careers in Academic Medicine, 2011
- UNC Urology Resident Scholar Award, 2011 (highest percentile on Urology in-service exam)
- North Carolina Resident Symposium, 1st place, debate, 2010
- Montague L. Boyd Essay Competition, 3rd place, Research Competition, Southeastern Section, American Urological Association, 2010
- North Carolina Resident Symposium, 2nd place, research presentation, 2009
- North Carolina Resident Symposium, 1st place, case presentation, 2008
- UNC Eskelund Award for Excellence in Pediatric Surgery, 2008
- North Carolina Resident Symposium, 1st place, research presentation, 2007

- Alpha Omega Alpha Honor Medical Society, University of North Carolina Gamma Chapter, 2006
- Medical Alumni Loyalty Fund Scholarship, 2005-2006
- Frank Porter Graham Graduate and Professional Student Honor Society, 2005
- *Phi Beta Kappa* Academic Honor Society, 2003
- Golden Key National Honor Society, 1996
- *Delta Omega* award (Honor Society in Public Health), 2003 (valedictorian of the UNC biostatistics graduating class)
- *Phi Sigma Pi* Lamp of Knowledge for Outstanding Scholarship, 2001 & 2003
- UNC Johnston Scholar, 1999 – 2003

BIBLIOGRAPHY AND PRODUCTS OF SCHOLARSHIP

Published Book Chapters

1. **Smith AB**, Filippou P (2021) "The Role of Partial Cystectomy for Primary Surgical Management of Muscle Invasive Bladder Cancer" *BJUI Knowledge*, Published 2018, Revised 2021, <https://bjuiknowledge.bjuinternational.com/modules/role-of-partial-cystectomy-primary-surgical-management-of-muscle-invasive-bladder-cancer/>
2. **Smith AB**, Pruthi RS (2020) "Robotic-Assisted Radical Cystectomy Outcomes" in "Robotic Surgery, 2nd Edition." Gharagozloo F, Meyer M, Giulianotti P, Gruessner R, Poston R, Patel V. Springer Nature.
3. **Smith AB** (2017). "Commentary on Pelvic Lymph Node Dissection" in *Hinman's Atlas of Urologic Surgery*, 4e, Smith J, Howards S, Preminger G, Dmochowski R (Eds.), Elsevier, p. 594-596.
4. Kallingal GJ, **Smith AB**, Parekh, Pruthi RS (2015). "Laparoscopic/Robotic Radical Cystectomy and Urinary Diversion- Clinical Trials" in *Bladder Cancer: Diagnosis and Clinical Management*, Lerner S, Sternberg C, Schoenberg M, (Eds.), Wiley-Blackwell, p. 167-176.
5. **Smith A**, Pruthi RS (2014). "Ureter & Renal Pelvis, SCC" in *The 5-Minute Urology Consult*, 3rd Ed., Gomella, Leonard G, Lippincott Williams & Wilkins, p. 542-544.
6. **Smith A**, Woods M (2014). "Robotic Cystectomy- Avoidance of Surgical Complications" in *Robotic Surgery of the Bladder*, Pruthi RS and Castle EK, (Eds.), Springer, p. 159-171.
7. **Smith A**, Milowsky M, Chen R (2014). "Chapter 83: Bladder Cancer" in *Abeloff's Clinical Oncology*, 5th Ed. Niederhuber, Armitage, Doroshow, Kastan, and Tepper (Eds.), Elsevier, p. 1445-1463.
8. **Smith A**, Pruthi RS. (2013) "Chapter 81: Prostate Cancer Counterpoint," in *Patient Surveillance after Cancer Treatment (Current Clinical Oncology)*, Johnson F, et al. (Eds.), Springerlink, p.403-411.

In Press/Submitted Book Chapters

1. Avulova S, **Smith AB** (2021). Bladder Cancer in Women. AUA Update Series. May 2021. In press. 20 pages.

Published Refereed Papers/Articles

*indicates trainee

†indicates DEI trainee

‡indicates product of interdisciplinary scholarship

Original Research

1. **Smith AB**, Lee JR, Lawrence SO, Lavalley DC, Chisolm S, MacLean D, Louwers R, Wolff EM, Kessler L, Follmer K, Gore JL. Patient and Public Involvement in the Design and Conduct of a Large Pragmatic Observational Trial to Investigate Recurrent High-risk Non-Muscle Invasive Bladder Cancer. *Cancer*. 2022 Jan; 128(1):103-111. PMID: 34495550
2. Mody G, Stover A, Wang M, Jansen J, Henson S, Chung AE, Jonsson M, Bennet A, **Smith AB**, Wood W, Deal A, Ginos B, Dueck AC, Schrag D, Basch E. Patient-reported Symptoms during Lung Cancer Chemotherapy; a Nested Cohort within the PRO-TECT Pragmatic Trial (AFT-39) *Lung Cancer* 2021, 162:1-8; PMID: 34634754.
3. **Smith AB**, McCabe S, Deal AM, Guo A, Gessner KH, Lipman R, Chisolm S, Ahlschlager L, Gore JL. Quality of Life and Health State Utilities in Bladder Cancer. *Bladder Cancer*, 2021 December. Online ahead of print.
4. Russo GI, Shalklapper T, Cocci A, Broggi G, Caltabiano R, **Smith AB**, Lotan Y, Morgia G, Kamat A, Witjes JA, Daneshmand S, Desai M, Gill I, Cacciamani GE. Performance Of Narrow Band Imaging (Nbi) And Photodynamic Diagnosis (Pdd) Fluorescence Imaging Compared To White Light Cystoscopy (Wlc) In Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review And Lesion-Level Diagnostic Meta-Analysis. *Cancers (Basel)*; 2021 Aug; 13(17):4378. PMID: 34503188.
5. ‡Rose T, Weir WH, Mayhew GM, Shibata Y. Eulitt P, Uronis JM, Nielsen M, **Smith AB**, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY. Fibroblast Growth Factor Receptor 3 Alterations and Response to Immune Checkpoint Inhibition in Metastatic Urothelial Cancer: A Real World Experience. *British Journal of Cancer*, 2021 Oct; 125(9):1251-1260. PMID: 34294892.
6. Ferraris F, Yaber F, **Smith AB**, Barreiro D. The end of “very low risk” in Localized Prostate Cancer? *Prostate* 2021 Jul;87(10):615-617 PMID: 34010453.
7. ‡Bhanvadia S, Psutka S, Burg M, Wit R, Dhillon H, Gyawali B, Morgans A, Goldstein D, **Smith AB**, Sun M, Penson D. Financial Toxicity Amongst Patients with Prostate, Bladder and Kidney Cancer: A Systematic Review and Call to Action. *EU Oncology* 2021 Jun;4(3): 396-404. PMID: 33820747.
8. ‡Shabsigh A, Kleinmann N, **Smith AB**, Scherr D, Seltzer E, Schoenberg M, Lerner SP. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. *Cancer Chemotherapy and Pharmacology* 2021 Jun; 87(6):799-805. PMID: 33677615.
9. *†‡Mohan CS, Rotter JS, Tan H-J, Kent E, Bjurlin MA, Basch E, Samuel C, Nielsen ME, **Smith AB**. The Association between Patient Experience and Healthcare Outcomes Using SEER-CAHPS Patient Experience and Outcomes among Cancer Survivors. *Journal of Geriatric Oncology*. 2021 May;12(4):623-631. PMID: 33277226.
10. *†Demzik A and Filippou P, Chew C, Deal A, Mercer E, Mahajan S, Wallen EM, Tan HJ, **Smith AB**. ‘Gender-based Differences in Urology Residency Applicant Personal Statements.’ *Urology*. 2021 Apr; 150:2-8. PMID 33035562.
11. *†Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, **Smith AB**. Assessing Contemporary Trends in Female Speakership within Urologic Oncology. *Urology*. 2021 Apr;150:41-46. PMID 32798517.

12. *†‡Chyu J and Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T, **Smith AB**, Porten SP, Greene K, Browning N, Harris E, Sutherland SE, Psutka, SP. Women in Leadership in Urology: The Case for Increasing Diversity and Equity. *Urology*. 2021 Apr;150:16-24 PMID 32961220.
13. ‡McMahon S, Basak R, Zhou X, **Smith AB**, Song L, Pruthi RS, Wallen EM, Nielsen ME, Tan HJ. Patient-reported Health Status, Comorbidity Burden, and Prostate Cancer Treatment. *Urology*. 2021 Mar; 149:103-109. PMID: 33352164.
14. *†‡Hamad J, Gore J, Chisolm S, Powell M, Lavalley DC, Lipman R, Lindsey N, **Smith AB**. Patient empowerment through engagement in bladder cancer research. *Urol Oncol*. 2021 Mar;39(3):193.e13-193.e19. PMID: 32863122.
15. *†‡Ahrang J, Song L, Snyder E, Louwers RK, Sachse K, Chisolm S, Gore J, **Smith AB**. Well-being and Perceptions of Supportive Resources among Caregivers of Patients with Bladder Cancer. *Bladder Cancer*. 2021 March;7(1)43-52.
16. *†‡Gessner KH, Jung J, Cook HE, Graves JL, McNaull P, Chidgey B, Mann J, Woody N, Deal AM, Coward RM, Figler B, Borawski K, Bjurlin MA, Raynor M, Tan HJ, Viprakasit D, Wallen EM, Nielsen ME, **Smith AB**. Implementation of Post-operative Standard Opioid Prescribing Schedules Reduces Opioid Prescriptions Without Change in Patient-Reported Pain Outcomes. *Urology*. 2021 Feb;148:126-133 PMID 33217455
17. ‡Tan HJ, Zhou X, Spratte BN, McMahon S, Nielsen ME, Lund J, Harris AHS, **Smith AB**, Basch E. Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. *J Urol* 2021 Feb;205(2):434-440 PMID 32909877
18. Linehan J, Prescott M, Schoenberg M, **Smith AB**. Complication Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma. *Urology*, 2021 Jan;147:87-95 PMID 33031842.
19. *†‡Osterman CK, Deal AM, McCloskey H, Nyrop KA, Bjurlin MA, Tan HJ, Nielsen ME, Milowsky MI, Muss HB, **Smith AB**. Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle Invasive Bladder Cancer. *J Urol*. 2021 Jan;205(1):94-99. PMID: 32716672; PMCID: PMC7952031.
20. Loeb S, Reines K, Salha-Abu, Yousef, French W, Butaney M, Macaluso J, Steinberg G, Walter D, Byrne N, de la Garza, D, **Smith AB**. Quality of Bladder Cancer Information on YouTube. *European Urology*, 2021 Jan;79(1):56-59. PMID 33010986
21. *Ehlers M, Bjurlin M, Gore J, Pruthi R, Narang G, Tan HJ, Nielsen ME, Zhu A, Deal A, **Smith AB**. A National Cross-Sectional Survey of Financial Toxicity Among Bladder Cancer Patients. *Urologic Oncology* 2021 Jan;39(1):76.e1-76.e7 PMID: 33268274
22. ‡**Smith AB**, Samuel CA, McCabe SD, Deal AM, Jonsson M, Mueller DE, Mahbooba ZM, Bennett AV, Chung AE, Nielsen ME, Tan HJ, Wallen EM, Pruthi RS, Wang A, Basch E, Reeve BB, Chen RC. Feasibility and Delivery of Patient-Reported Outcomes in Clinical Practice Among Racially Diverse Bladder and Prostate Cancer Patients. *Urologic Oncology*. 2021 Jan;39(1):77.e1-77.e8. PMID: 32819814
23. ‡Eulitt P, Ersan A, Sheikh A, Wong T, Woods M, Rose TL, Wallen E, Pruthi R, **Smith AB**, Nielsen M, Whang Y, Kim W, Godley P, Basch E, David G, Ramirez J, Deal A, Rathmell KW, Chen R, Bjurlin M, Lin W, Lee J, Milowsky M. Pilot Study of Flurodeoxyglucose Positron Emission Tomography (FDG-PET)-Magnetic Resonance Imaging (MRI) for Staging Muscle-Invasive Bladder Cancer (MIBC) *Clinical Genitourinary Cancer*. 2020 Oct; 18(5):378-386. PMID: 32147364.

24. ‡Auffenberg, G, **Smith AB**, Averch, T, Barth R, Borza T, Brummett C, Chidgey B, Davies B, Dupree J, Ehdaie B, Nielsen ME, Pais V, Rukstalis M, Sperandeo-Fruge, M, Stulberg J, Waljee J, Winiecki S. Opioid Stewardship in Urology: American Urological Quality Improvement Summit. *Urology Practice* 2020 Sep; Vol. 7, Issue 5.
25. Leow JJ, Catto JW, Efstathiou JA, Hussein AA, Shariat SF, **Smith AB**, Weizer AZ, Wirth M, Witjes JA, Trinh QD. Quality Indicators for Bladder Cancer Services. *Eur Urol.*; 2020 Jul;78(1):43-59 PMID 31563501.
26. Shabsigh A, Kleinmann N, **Smith AB**, Scherr D, Seltzer E, Schoenberg M, Lerner S. Pharmacokinetics of UGN-101, a Mitomycin-containing Reverse Thermal Gel Instilled via Retrograde Catheter for the Treatment of low-grade Upper Tract Urothelial Carcinoma. *Lancet Oncology*. 2020 Jun;21(6):776-785 PMID 32631491
27. Kleinmann N, Surena F, Matin MD, Pierorazo P, Gore J, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman J, Knoedler J, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, **Smith AB**, Linehan J, Coleman J, Humphreys M, Pak R, Lifshitz D, Verni M, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner S. Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel – The OLYMPUS Trial. *Lancet Oncology* 2020 June. PMID 32631491.
28. Lam, C, Warren JL, Nielsen ME, **Smith AB**, Boyd E, Barrett MJ, Mariotto A. Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. *JNCI*. 2020 May (55):31-38. PMID 32412074
29. *†Gan ZS, Wood CM, Hayon S, Deal A, **Smith AB**, Tan HJ, Pruthi RS. Correlation of Relative Value Units with Surgical Complexity and Physician Workload in Urology. *Urology*. 2020 May PMID: 32084413.
30. *†Hamad J, McCloskey, H, Millowsky, MI, Royce, T, **Smith AB**. Bladder Preservation in Muscle-Invasive Bladder Cancer, A Comprehensive Review. *Brazil Journal of Urology* 2020 Mar-Apr; 46(2):169-184; PMID 31961624
31. ‡Samuel, C.A., **Smith, AB.**, Elkins, W., Richmond, J., Mahbooba, Z., Basch, E., Bennett, A., Chung, A., Jonsson, M., Chen, R., Reeve, B. Racial Differences in User Experiences and Perceived Value of Electronic Symptom Monitoring in a Cohort of Black and White Bladder and Prostate Cancer Patients. *Quality of Life Research*. 2020 February. Online ahead of print. PMID 32112276
32. *Raskolnikov D, Brown BB, Holt SK, Ball AL, Lotan Y, Strobe S, Shroeck F, Ullman R, Lipman R, **Smith AB**, Gore JL. Reduction of Pain During Flexible Cystoscopy: A Systematic Review and Meta-Analysis. *J Urol* 2019 Dec; 202(6):1136-1142; PMID 31219763.
33. ‡McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, **Smith AB**, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH. Development and acceptability testing of a patient decision aid for urinary diversion with radical cystectomy. *J Urol*. 2019 Nov; 202(5):1001-1007. PMID: 31099720.
34. **Smith AB**, Mueller D, Garren B, Tan HJ, Wallen EM, Woods ME, Pruthi R, Nielsen M. Qualitative Research to Reduce Readmissions and Optimize Perioperative Cystectomy Care. *Cancer*. 2019 Oct; 125(20):3545-3553. PMID: 31299091.
35. Lotan Y, Bivalacqua T, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom P, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, **Smith AB**, Steinberg S, Trabulsi E, Woods M, and Daneshmand S. Optimal Use of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in non-muscle invasive bladder cancer. *Nature Reviews Urology*, 2019 Jun; 16(6);377-386. PMID 31019310.

36. *‡Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, **Smith AB**, Jacobs BL. Palliative care use amongst patients with bladder cancer. *BJU Int*. 2019 Jun; 123(6):968-975.. PMID: 3078125.
37. Mossanen M, Chu A, **Smith AB**, Gore JL. Inferring bladder cancer research prioritization from patient-generated online content. *World J Urol*. 2019 Jun; 37(6):1145-1150. PMID: 30203340
38. **Smith AB**, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y, Flexible Blue Light Study Group Collaborators. Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinic Acid (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study. *BJU Int*, 2019 Jan;123(1): 35-41. PMID: 29979488.
39. Taylor J, Meng X, Renson A, **Smith AB**, Wysock JS, Taneja SS, Huang WC, Bjurlin MA. Different models for prediction of radical cystectomy postoperative complications and care pathways. *Ther Adv Urol*. 2019 Jan-Dec; PMID: 31565072; PMCID: PMC6755632.
40. Bjurlin MA, **Smith AB**, Huang WC. Impact of immunonutrition on radical cystectomy immunoresponse and outcomes; opportunity for peri-operative optimization. *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S760-S762. PMID 30687620.
41. **Smith AB**, Chisolm S, Deal A, Spangler A, Quale DZ, Bangs R, Jones JM, Gore JL. Patient-centered prioritization of bladder cancer research. *Cancer*. 2018 Aug 1;124(15): 3136-3144. PMID: 29727033.
42. **Smith AB**, Meyer AM, Meng K, Pruthi RS, Wallen EM, Woods ME, Nielsen ME. Investigating travel distance as predictor of treatment of Muscle-invasive bladder cancer in a unique multi-payer state database. *Urol Onc*. 2018 Jun; 36(6):308.e1-308.e9. PMID: 29566978.
43. *†Casilla-Lennon MM, Choi SK, Deal AM, Bensen JT, Narang G, Filippou P, McCormick B, Pruthi R, Wallen EM, Tan HJ, Woods M, Nielsen M, **Smith AB**. Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life. *J Urol*. 2018 May;199(5): 1166-1173. PMCID: PMC5947876; PMID: 29155338.
44. **Smith AB**, Jaeger B, Pinheiro LC, Edwards LJ, Tan HJ, Nielsen ME, Reeve BB. The impact of bladder cancer on health-related quality of life. *BJUI*. 2018 Apr; 121(4): 549-557. PMID: 28990272.
45. Mossanen M, Krasnow RE, Lipsitz SR, Preston MA, Kibel AS, Ha A, Gore JL, **Smith AB**, Change SL. Associations of specific postoperative complications with outcomes after radical cystectomy. *BJUI*. 2018 Mar; 121(3): 428-436. PMID: 29063725.
46. *†Pham MN, Deal AM, Ferguson JE III, Wang Y, **Smith AB**, Nielsen ME, Pruthi RS. Contemporary survival trends in penile cancer: Results from the National Cancer Database. *Urologic Oncology*. 2017 Dec;35(12):674.e1-674.e9. PMID: 28882672.
47. *†Filippou P, **Smith AB**. Prioritizing the patient voice in the development of urologic oncology research. *Urol Oncol*. 2017 Sep; 35(9): 548-551. PMID: 28688774.
48. *†Narang GL, Pannell SC, Laviana AA, Huen KHY, Izard J, **Smith AB**, Bergman J. Patient-reported outcome measures in urology. *Curr Opin Urol*. 2017 Jul; 27(4): 366-374. PMID: 28505039
49. *†Sukhu T, Pruthi NR, Deal AM, Langston J, Kirby EW, Raynor MC, Gonzalez C, McKenna P, **Smith AB**, Pruthi RS. Workforce Characteristics in Urology. *Urology Practice*. 2017; 5(2): 150-154.
50. ‡Kardos J, Wobker S, Woods M, Nielsen ME, **Smith AB**, Wallen EM, Pruthi RS, Hayward M, Grilley-Olson J,

Patel N, Weck K, Black P, Parker JS, Milowsky M, Kim WY. Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities with Colorectal Cancer Including a Hypermutable Phenotype. *JCO Precision Oncology*, 2017 July. eCollection. PMID 32913973

51. ‡Stitzenberg KB, Chang YK, **Smith AB**, Meyers MO, Nielsen ME. Impact of location of readmission on outcomes after major cancer surgery. *Annals of Surgical Oncology*. 2017 Feb;24(2):319-329. PMID: 27613557.
52. **Smith AB**, Crowell K, Woods ME, Wallen EM, Pruthi RS, Nielsen ME, Lee CT. Functional Outcomes Following Radical Cystectomy in Women with Bladder Cancer: A Systematic Review Article. *European Urology Focus*. 2017 Feb;3(1):136-143. PMID: 28720359.
53. *McKibben MJ, Kirby EW, Langston J, Raynor MC, Nielsen ME, **Smith AB**, Wallen EM, Woods ME, Pruthi RS. Projecting the urology workforce over the next 20 years. *Urology*. 2016 Dec;98:21-26. PMID: 27491965.
54. ‡Rose TL, Deal AM, Krishnan B, Nielsen ME, **Smith AB**, Kim WY, Milowsky M. Racial disparities in survival in metastatic renal cell carcinoma in the targeted therapy era. *Cancer*. 2016 Oct; 122(19):2988-95. PMID: 27341404.
55. ‡Mak, KS, **Smith AB**, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-Term Survivors of Muscle-Invasive Bladder Cancer. *Int. Journal of Radiation, Oncology, Biology, Physics*. 2016 Aug. PMID: 27727064.
56. ‡Rose TL, Deal AM, Nielsen ME, **Smith AB**, Milowsky MI. Sex disparities in chemotherapy use and survival in patients with advanced bladder cancer. *Cancer*. 2016 Jul 1; 122(13):2012-20. PMID: 27224661.
57. ‡Ording AG, Nielsen ME, **Smith AB**, Horváth-Puhó E, Sørensen HT. Venous thromboembolism and impact of comorbidity in bladder cancer: a Danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011. *Urologic Oncology*. 2016 Jul;34(7):292.e1-8. PMID: 26971189.
58. ‡Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, **Smith AB**, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. *Clin Cancer Res*. 2016 Jun 15; 22(12):2950-9. PMID: 26787754.
59. *Johnson DC, Mueller DE, Deal AM, Dunn MW, **Smith AB**, Woods ME, Wallen EM, Pruthi RS, Nielsen ME. Integrating patient preferences into treatment decisions for men with prostate cancer at the point of care. *J Urol*. 2016 Jun 23. PMID: 27346032.
60. *Janda G, Deal A, Yang H, Nielsen M, **Smith A**, Pruthi RS, Wallen E, Woods M, Raynor M. Single-institution experience with robotic partial nephrectomy for renal masses greater than 4 cm. *J Endourol*. 2016 Apr;30(4):384-9. PMID: 26597172
61. ‡Falchook A, Martin N, Ramsankar B, **Smith AB**, Milowsky M, Chen R. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate specific antigen. *Urol Oncol*. Urol Oncol. 2016 Mar; 34(3):119.e19-26. PMID: 26526383.
62. *†Spencer ES, Deal AM, Pruthi NR, Gonzalez CM, Kirby EW, Langston J, McKenna PH, McKibben MJ, Nielsen ME, Raynor MC, Wallen EM, Woods ME, Pruthi RS, **Smith AB**. Gender differences in compensation, job satisfaction, and other practice patterns in urology. *J Urol*. 2016 Feb; 195(2):450-5. PMID: 26384452.
63. ‡*Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**, Milowsky MI. Neoadjuvant chemotherapy

administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. *Urol Oncol*. 2015 Sep;33(9):386.e1-6. PMID: 26122712.

64. *Johnson DC, Riggs SB, Nielsen ME, Matthews JE, Woods ME, Wallen EM, Pruthi RS, **Smith AB**. Nutritional predictors of complications following radical cystectomy. *World Journal of Urology* 2015 Aug; 33(8): 1129-37. PMID: 25240535
65. *McMillan DT, Viera AJ, Matthews J, Raynor MC, Woods ME, Pruthi RS, Wallen EM, Nielsen ME, **Smith AB**. Resident involvement and experience as predictive factors for peri-operative outcomes following robotic prostatectomy. *World J of Urol*. 2015 Jun; 33(6): 793-9. PMID: 24985554.
66. ‡Tan HJ, Meyer AM, Kuo TM, **Smith AB**, Wheeler SB, Carpenter WR, Nielsen ME. Provider-based research networks and the diffusion of surgical technologies among patients with early-stage kidney cancer. *Cancer*. 2015 Mar. 121(6):836-43. PMID: 25410684. PMCID: PMC4352108.
67. *†Pruthi A, Nielsen ME, Raynor MC, Woods ME, Wallen EM, **Smith AB**. Readability of American online patient education materials in urologic oncology: a need for simple communication. *Urology*. Feb 2015; 85(2): 351-6. PMID: 25623686. PMCID: PMC4308671.
68. ‡Stitzenberg KB, Chang Y, **Smith AB**, Nielsen ME. Exploring the burden of inpatient readmissions after major cancer surgery. *J Clin Oncol*. Feb 2015; 33(5): 45-64. PMID: 25547502. PMCID: PMC4314594.
69. *†Feng MA, McMillan DT, Crowell K, Muss H, Nielsen ME, **Smith AB**. Geriatric assessment as a prognostic tool in surgical oncology: a systematic review. *J of Surgical Research*. 2015 Jan;193(1): 265-72. PMID: 25091339.
70. *‡Johnson DC, Vukina J, **Smith AB**, Meyer AM, Wheeler SB, Kuo TM, Woods ME, Raynor MC, Wallen EM, Pruthi RS, Nielsen ME. Preoperative misclassified, surgically removed benign renal masses: a systematic review and United States population-level burden estimate. *J Urol*. 2015 Jan; 193(1):30-5. PMID: 25072182.
71. *Fifer GL, Raynor MC, Selph P, Woods ME, Wallen EM, Viprakasit DP, Nielsen ME, **Smith A**, Pruthi RS. Robotic ureteral reconstruction distal to the ureteropelvic junction: a large single institution clinical series with short-term follow up. *J Endourol*. 2014 Dec; 28(12):1424-8. PMID:25230048.
72. **Smith AB**, Deal AM, Woods ME, Wallen EM, Pruthi RS, Milowsky MI, Nielsen ME. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. *BJU Int*. 2014 Nov; 114(5):719-26. PMID: 24325202.
73. ‡Davis CF, Ricketts C, Wang M, Yang L, Chmiack A, Shen H, Buhay C, Kang H, Kim SC, Fahye CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaiparettu BA, Bristow CA, Donehower LA, Wallen EM, **Smith AB**, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, TCGA Research Network, Chin L, Meyerson M, Kucherlapati R, Park, WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Chuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ. The Somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell*. 2014 Sep 8; 26(3):319-30. PMID: 25155756.
74. *Johnson DC, Nielsen ME, Matthew J, Woods ME, Wallen EM, Pruthi RS, Milowsky MI, **Smith AB**. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. *BJU Int*. 2014 Aug; 114(2): 221-8. PMID: 24274722.
75. ‡**Smith AB**, Deal AM, Yu H, Boyd B, Matthews J, Wallen EM, Pruthi RS, Woods ME, Muss H, Nielsen ME. Sarcopenia as a predictor for complications and survival following radical cystectomy. *J Urol*. 2014 Jun; 191(6): 1714-20. PMID: 24423437.

76. *Selph PJ, Whited WM, **Smith AB**, Matthews J, Pruthi RS, Wallen EM, Nielsen ME, Woods ME. Metabolic syndrome as a predictor for postoperative complications following urologic surgery. *Urology*. 2014 May; 83(5):1051-9. PMID: 24656508.
77. **Smith AB**, Horváth-Puhó E, Nielsen ME, Lash TL, Baron JA, Sørensen HT. Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma. *Urologic Oncology*. 2014 May; 32(4): 466-72. PMID: 24767684, PMCID: PMC4017852
78. *Langston JP, Kirby EW, Nielsen ME, **Smith AB**, Woods ME, Wallen EM, Pruthi RS. Economic Impact of Training and Career Decisions in Urologic Surgery. *J Urol*. 2014 Mar; 191(3):755-60. PMID: 24096119.
79. ‡Nielsen ME, **Smith AB**, Meyer AM, Kuo TM, Tyree S, Kim WY, Milowsky MI, Pruthi RS, Millikan RC. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. *Cancer*. 2014 Jan; 120(1):86-95. PMID: 24122346
80. ‡*†Gallagher SA, **Smith AB**, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell KW, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database- UNC GOLD. *Urol Oncol*. 2014 Jan; 32(1):32-40. PMID 23434424.
81. **Smith AB**, Maizels M, Wiener J, Sutherland RW. A Novel method of teaching surgical techniques to residents-computerized enhanced visual learning (CEVL) with simulation to certify mastery of training: a model using newborn clamp circumcision. *J of Ped Urol*. 2013 Dec; 9(6 Pt B): 1210-3. PMID 23937953.
82. Mmeje CO, Nunez-Nateras R, Nielsen ME, Pruthi RS, **Smith A**, Wallen EM, Humphreys MR, Woods ME, Castle EP. Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robotic assisted radical cystectomy: With mean follow-up of 3.5 years. *Urol Oncol*. 2013 Nov; 31(8):162-7. PMID 22534088.
83. **Smith AB**, Woods ME, Raynor MC, Nielsen ME, Wallen EM, Pruthi RS. Prevention and management of complications following robot-assisted radical cystectomy: lessons learned after >250 consecutive cases. *World J Urol*. 2013 June; 31(3):441-446. PMID 23269587.
84. Raynor MC, **Smith A**, Vyas SN, Selph JP, Carson CC. Dorsal penile nerve block prior to inflatable penile prosthesis placement: a randomized, placebo-controlled trial. *J Sex Med*. 2012 Nov; 9(11):2975-9. PMID 22642415.
85. Nielsen ME, **Smith AB**, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the bladder cancer advocacy network (BCAN) survey. *BJU Int*. 2012 Oct; 110(7):967-72. PMID 22487336.
86. **Smith AB**, Raynor M, Amling CL, Busby JE, Castle E, Davis R, Nielsen M, Thomas R, Wallen EM, Woods M, Pruthi RS. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. *J Laparoscopic Adv Surg Tech A*. 2012 Jan-Feb; 22(1):17-21. PMID 22142028.
87. Coward M, **Smith A**, Raynor M, Nielsen M, Wallen EM, Pruthi RS. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in older patients. *Urology*. 2011 May; 77(5):111-4. Epub 2011 Feb 18. PMID 21333341.
88. ‡Pruthi RS, Nielsen M, Heathcote S, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, **Smith A**, Kim W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing cystectomy: clinical and pathological results. *BJU International*. 2010 Aug; 106(3):349-54. PMID: 20089114.

89. **Smith A**, Kurpad R, Lal A, Nielsen M, Wallen EM, Pruthi RS. Cost analysis of robotic versus open radical cystectomy for bladder cancer. *Journal of Urology*. 2010 Feb; 183(2):505-9. PMID: 20006882.
90. Pruthi RS, Nielsen ME, Nix J, **Smith A**, Schultz H, Wallen EM. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. *Journal of Urology*. 2010 Feb;183(2):510-4. PMID: 20006884.
91. Nix J, **Smith A**, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. *European Urology*. 2010 Feb; 57(2):196-201. PMID: 19853987.
92. Pruthi RS, Nielsen M, **Smith A**, Nix J, Schultz H, Wallen EM. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. *J Am Coll Surg*. 2010 Jan; 210(1):93-99. PMID: 20123338.
93. Pruthi RS, **Smith A**, Wallen EM. Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy, *Journal of Endourology*. 2008 Nov; 22(11):2469-74. PMID: 19046088.
94. Miller J, **Smith A**, Kouba E, Wallen E, Pruthi RS. Prospective evaluation of short-term impact and recovery of health related quality of life in men undergoing assisted laparoscopic radical prostatectomy versus open radical prostatectomy. *Journal of Urology*. 2007 Sep; 178(3 Pt 1): 854-8; discussion 859. PMID: 17631338.
95. Kouba E, **Smith A**, Derksen J, Gunn K, Wallen E, Pruthi R. Efficacy and safety of en bloc ligation of the renal hilum during laparoscopic nephrectomy. *Urology* 2007 Feb;69 (2): 226-9. PMID: 17275073.
96. Kouba E, **Smith A**, McRackan D, Wallen E, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history of solid renal masses and results of delayed intervention, *Journal of Urology* 2007 Feb; 177(2): 466-70; discussion 470. PMID: 17222611.
97. York D, **Smith A**, von Allmen D, Phillips JD. Laparoscopic appendectomy in children after the learning curve, *Journal of the Society of Laparoscopic Surgeons*, 2006 Oct-Dec; 10(4): 447-52. PMID: 17575755.
98. York D, **Smith A**, Phillips JD, von Allmen D. The influence of advanced radiographic imaging on the treatment of pediatric appendicitis. *Journal of Pediatric Surgery*. 2005; 40: 1908-11. PMID: 16338316.
99. Adelberg AM, **Blotzer A**, Koch G, Moise R, Chescheir N, Wolfe H. Impact of maternal fetal surgery for myelomeningocele on the progression of ventriculomegaly in utero. *American Journal of Obstetric & Gynecology*. 2005 Sept; 193(3 Pt 1):727-31. PMID: 16150266.
100. Sloane PD, Beck R, Kowlowitz V, **Blotzer AM**, Wang L, Akins L, White-Chu F, Mitchell CM. Behavioral coding for evaluation of medical student communication: clarification or obfuscation? *Acad Med*. 2004 Feb;79(2):162-70. PMID: 14744718.

Other Peer-Reviewed Articles:

1. *†Hacker KE, **Smith AB**. Engaging Stakeholders and Patient Partners. *Surg Oncol Clin N Am*. 2018 Oct;27(4):665-673. PMID: 30213411
2. Brooke BS, **Smith AB**, Ghaferi AA. Past and Future Role of the Surgical Outcomes Club in Advancing Surgical Outcomes and Health Services Research. *JAMA Surg*. 2018 Aug 29. PMID: 30167634
3. *Mossanen M, **Smith AB**. Addressing Financial Toxicity: The Role of the Urologist. *Journal of Urology*. 2018 Jul; 200(1):43-45. PMID: 29113839.

4. **Smith AB.** Recent developments in the management of bladder cancer: Introduction. *Urologic Oncology*. 2018 Mar; 36(3):95-96. PMID: 29158137.
5. **Smith AB,** Schwarze ML. Translating patient-reported outcomes from surgical research to clinical care. *JAMA Surg*. 2017 Sep; 152(9): 811-812. PMID: 28636695.
6. **Smith AB,** Basch E. Role of patient-reported outcomes in postsurgical monitoring in oncology. *Journal of Oncology Practice*. 2017 Aug;13(8): 535-538. PMID: 28682667.
7. ‡Apollo AB, Hoffman V, Kaag MG, Latini D, Lee CT, Rosenberg J, Knowles M, Theodorescu D, Czerniak B, Efstathiou J, Albert M, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat A, Flaig T, **Smith A,** Messing E, Quale D, Lotan Y. Summary of the 8th annual bladder cancer think tank: collaborating to move research forward. *Urologic Oncology*. 2015 Feb; 33(2): 53-64. PMID 25065704.
8. *Kirby EW, Borawski KM, **Smith AB.** Levels of evidence and clinical guidelines- considerations for the practicing urologist. *Sex Med Rev*. 2013; 1:17-23.
9. **Smith AB,** Raynor MC, Pruthi RS. Peri- and postoperative outcomes of robot-assisted radical cystectomy (RARC). *BJU Int*. 2011 Sep; 108(6 Pt 2):969-75. PMID: 21917099.
10. **Smith A,** Nielsen ME, Wallen EM, Pruthi RS. Current status of robot-assisted radical cystectomy. *Current Opinion in Urology*. 2010 Jan; 20(1):60-4. PMID: 19875962.
11. **Smith A,** Carson C. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. *Therapeutics and Clinical Risk Management*, 2009 June; 5(3):535-45. PMID: 19707263.
12. Nusbaum MRH, Frasier PY, Tudor G, **Smith AM,** Means G, DeVellis RF. Women’s Sexual Health Care Needs: Variation by Age. *Journal of Family Communication*, 2005.
13. Nusbaum MRH, Frasier PY, Tudor G, **Smith AM,** Means G, DeVellis RF. Women’s sexual health needs: variation by age and sexual concern typology. *Women's Health Issues*, 2005.

Published Abstracts (Poster/Podium Presentations):

1. Filippou, P, Hugar LA, Sekar RR, Louwers RR, Pomper A, Chisolm S, **Smith AB,** Gilbert SM, Gore JL. 'Palliative care experiences and attitudes among patient and caregiver participants in the Bladder Cancer Advocacy Network Patient Survey Network.' Moderated poster presentation at the American Urological Association Annual Meeting, Las Vegas, NV, September 2021.
2. Stover AM, Kurtzman R, **Smith AB,** Chung AE. What are the training needs of primary care stakeholders to implement clinic-wide depression screening with PROMs?: stakeholder perceptions and lessons learned. Symposium title: “Putting the horse before the cart: understanding the needs and individual factors influencing health care providers’ behaviour to integrate PROMs in daily practice.” Symposium under review at the annual meeting of the International Society for Quality of Life research (ISOQOL), Alberta, Canada, Virtual October, 2021. Virtual Presentation
3. Parris T, Hamad J, Mohan C, Basak R, Kent E, **Smith AB.** Time-to-Treatment After Cancer Diagnosis and The Patient Experience with Care: A SEER-CAHPS Study; Presented at: The Society of Urologic Oncology 21st Annual Meeting; 12/2-12/4, 2020; Virtual Presentation.
4. Parris T, Reines K, Basak R, Mueller D, **Smith AB;** Patient Perception of Repeat TURBT for Bladder Cancer; Presented at: The Society of Urologic Oncology 21st Annual Meeting; 12/2-12/4, 2020; Virtual Presentation.
5. **Smith AB,** Jung A, Song L, PEER, Hoffman-Censits J, Gore J. Evaluation of burden and needs assessment

among bladder cancer caregivers. Oncology Nursing Society Congress; April 12, 2019; Anaheim, CA

6. McCloskey H, McCabe S, Gessner K, Filippou P, Hamad J, Deal A, **Smith AB**, Gore J. "Cost-Effectiveness of Radical Cystectomy vs. Trimodality for Treatment of Muscle Invasive Bladder Cancer." Poster Presentation at the GU ASCO 2020, San Francisco, CA, February 14, 2020.
7. McCloskey H, McCabe S, Gessner K, Filippou P, Hamad J, Deal A, **Smith AB**, Gore J. "Cancer stage and quality of life in bladder cancer." Poster Presentation at the GU ASCO 2020, San Francisco, CA, February 14, 2020
8. Gessner K, McCabe S, Filippou P, McCloskey H, Hamad J, Deal A, Guo A, Gore J, **Smith AB**, "Bladder cancer caregiver quality of life and patient cancer severity." Poster Presentation at the GU ASCO 2020, San Francisco, CA, February 14, 2020.
9. Gessner KH, McCabe S, Filippou P, McCloskey H, Hamad J, Deal A, Gore J, **Smith AB**. "Bladder Cancer Caregiver Quality of Life and Patient Cancer Severity." Genitourinary Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO), San Francisco, February 2020.
10. Filippou P, McCabe S, McCloskey H, Gessner K, Hamad J, Deal AM, **Smith AB**, Gore JL. 'The impact of age on general and bladder cancer-specific quality of life among bladder cancer survivors.' Genitourinary American Society of Clinical Oncology Annual Meeting, San Francisco, CA, February 2020.
11. Filippou P, McCabe S, McCloskey H, Gessner K, Hamad J, Deal AM, **Smith AB**, Gore JL. 'Impact of bladder cancer stage on work impairment and financial toxicity.' Genitourinary American Society of Clinical Oncology Annual Meeting, San Francisco, CA, February 2020.
12. Suskovic N, Raldow A, Royce T, **Smith AB**. Cost-Effectiveness of Radical Cystectomy vs. Trimodality for Treatment of Muscle Invasive Bladder Cancer. Poster presentation at 2020 Genitourinary Cancers Symposium (abstract no. 575). February 2020
13. Hamad J, Gore JL, Chisolm S, Lipman R, **Smith AB**. 2019 Patient Survey Network Results and Future Directions. Podium Presentation at: Annual Meeting of the Society of Urologic Oncology; Washington, D.C. December 4, 2019.
14. Gessner KH, Jung J, Cook HE, Graves JL, McNaull P, Chidgey B, Mann J, Woody N, Coward RM, Figler B, Borawski K, Bjurlin M, Raynor M, Tan HJ, Viprasak D, Wallen E, Nielsen ME, **Smith AB**. Implementation of Post-operative Standard Opioid Prescribing Schedules Reduces Opioid Prescriptions Without Change in Patient-Reported Pain Outcomes. Society for Urologic Oncology Annual Meeting, Washington DC, December 2019.
15. Kukreja J, Schroeck F, Ehlers ME, Lotan Y, Gore J, **Smith AB**. Is Cystoscopy a Major Source of Discomfort and Anxiety for Bladder Cancer Patients? Oral Presentation at American College of Surgeons of Clinical Congress. San Francisco, California. October 29, 2019
16. Ehlers ME, Gore J, Chisolm S, Deal A, **Smith AB**. A Cross-Sectional Study Evaluating Financial Toxicity among Bladder Cancer Patients. Oral podium presentation at American College of Surgeons Clinic Congress. San Francisco, California. October 29, 2019
17. Yu F, **Smith AB**, Song, L. Information Seeking for Prostate Cancer Treatment Decision Making: A Natural Language Processing Approach to Analyzing Medical Communication During Consultation Visits. Oral presentation at the 2019 ICCH: International Conference on Communication in Healthcare. San Diego, California. October 27 - 30, 2019,
18. **Smith AB**, Wolff EM, Chisolm S, Lipman R, Gore J, Engaging Stakeholders in Urologic Research: the Patient-Centered Design of a Pragmatic Clinical Trial In Bladder Cancer. Podium, American Urologic Association Annual Meeting, Chicago IL, May 2019

19. Tan R, Basch E, **Smith AB**, PROs Vs. Claims: Predicting Life Expectancy for Men with Prostate Cancer –Poster, American Urologic Association Annual Meeting, Chicago IL, May 2019
20. Filippou P, Wang M, Samuel C, Bennett C, Chung A, Basch E, Chen R, Reeve B, **Smith AB**. Racial Differences in Patient-Reported Outcomes of Men Treated for Localized Prostate Cancer Poster, American Urologic Association Annual Meeting, Chicago IL, May 2019
21. Tan HJ, Chung A, Gotz D, **Smith AB**, Wallen E, Pruthi R, Nielsen ME. Disparate Access to Electronic Health Records and Quality Reporting among US Urologists. American Urologic Association Annual Meeting, San Francisco, CA, May 2018.
22. Hacker K, J Jae Jung, Graves JL, Cook HE, McHanull P, Chidgey B, Mann J, **Smith AB**, Nielsen ME. Post-operative opioid prescribing in urology: are we contributing to the national crisis? American Urologic Association Annual Meeting, San Francisco, CA, May 2018.
23. Garren B, Mueller D, Filippou P, Narang G, Nielsen M, Pruthi R, Wallen EM, Woods M, Tan HT, **Smith AB**. Importance of Patient-Reported Outcomes in Improving Perioperative Care Among Cystectomy Patients. American Urologic Association Annual Meeting, San Francisco, CA, May 2018.
24. Filippou P, Hacker KE, Deal AM, Mahajan S, Wallen EM, Pruthi RS, Wallen EM, Tan HJ, **Smith AB**. Gender bias in letters of recommendation for urology resident applicants. Society of Women in Urology Mentoring Conference, Las Vegas NV, January 2018.
25. Smith AB, Daneshmand S, Pohar K, Cookson M, Woods M, Trabulsi E, Huang W, Jones J, Taylor J, Bivalacqua T, O'Donnell M, Steinberg G, DeCastro J, Kamat A, Konety B, Resnick M, Schoenberg M, Jones S, Lotan Y. Assessment of Blue Light Flexible Cystoscopy with Cysview On Patient Reported Outcomes: A Prospective, Multicenter, Within–Patient Controlled Study In Detection of Bladder Cancer During Surveillance. Poster presentation at the Society of Urologic Oncology, Washington DC, December 2017.
26. Filippou P, Mahajan S, Deal A, Wallen EM, Pruthi RS, H Tan, **Smith AB**. ‘Gender bias in letters of recommendation for urology resident applicants.’ Podium presentation at the American College of Surgeons Clinical Congress, San Diego, CA, October 2017.
27. Narang G, Jaeger B, Pinheiro L, Edwards L, Reeve B, **Smith AB**. ‘Changes in Health-Related Quality of Life Among Older Adults with Prostate Cancer: A Case-Control Study.’ E-Poster presentation at American College of Surgeons Annual Clinical Congress. San Diego, Ca. October 2017.
28. Filippou P, Deal A, Narang G, McCormick BJ, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. ‘Patient refusal of neo-adjuvant chemotherapy for muscle invasive bladder cancer.’ Podium presentation at the American Urological Association Annual Meeting, Boston, MA, May 2017.
29. McCormick B, Jaeger B, Pinheiro L, Edwards L, Reeve B, **Smith A**. “Changes in Health-Related Quality of Life Among Older Adults with Prostate Cancer: A Case-Control Study.” American Urologic Association Annual Meeting. Boston, Massachusetts. May 2017. Poster Presentation.
30. Casilla–Lennon M, Cho S, Deal A, Benson J, Narang G, Filippou P, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith A**. “Financial Toxicity Prevalence and Delay in Care Among Bladder Cancer Patients.” American Urologic Association Annual Meeting. Boston, Massachusetts. May 2017. Poster Presentation.
31. Casilla–Lennon M, Cho S, Deal A, Benson J, Narang G, Filippou P, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith A**. “Financial Toxicity Prevalence and Quality of Life Among Bladder Cancer Patients.” American Urologic Association Annual Meeting. Boston, Massachusetts. May 2017. Poster Presentation.
32. McCormick B, Deal A, Filippou P, Narang G, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith**

- A. "Trends in the Use of Chemotherapy for Treatment of Upper Tract Urothelial Carcinoma Using the National Cancer Database." Society of Urologic Oncology 17th Annual Meeting, San Antonio, Texas. November 2016. Poster Presentation.
33. Casilla–Lennon M, Cho SK, Deal AM, Benson J, Narang G, Filippou P, McCormick B, Pruthi R, Wallen E, Woods ME, Nielsen ME, **Smith A**. 'Financial Toxicity Prevalence and Delay In Care Among Bladder Cancer Patients'. Society of Urologic Oncology annual meeting, San Antonio, TX, November 2016. Poster Presentation.
 34. Filippou P, Deal A, Narang G, McCormick B, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith AB**. Trends in patient refusal of neo-adjuvant chemotherapy for muscle invasive bladder cancer. Society of Urologic Oncology Annual Meeting, San Antonio, TX, November 2016. Poster Presentation.
 35. McCormick B, Deal A, Filippou P, Wallen E, Woods M, Pruthi R, Nielsen M, Tan H, **Smith AB**. Trends in the Use of Chemotherapy for Treatment of Upper Tract Urothelial Carcinoma Using the National Cancer Database. Society of Urologic Oncology 17th Annual Meeting, San Antonio, Texas. November 2016. Poster Presentation.
 36. M Macey, T Sukhu, J Lomboy, S Stanley, A Deal, D Mueller, M Nielsen, R Pruthi, E Wallen, M Woods, **A Smith**. *Understanding the Trajectory of Functional Status and Symptoms in the 90-Day Cystectomy Period*. American College of Surgeons Annual Clinical Congress (2016). Washington, D.C. October 2016. Podium Presentation.
 37. M Macey, J Langston, H Schultz, T Sukhu, J Lomboy, V Orcutt, E Kirby, M Nielsen, **A Smith**, R Pruthi. *Advanced Practice Providers in U.S. Urology*. American College of Surgeons Annual Clinical Congress (2016). Washington, D.C. October 2016. Podium Presentation.
 38. T Sukhu, J Lomboy, M Macey, A Deal, E Wallen, M Woods, R Pruthi, **A Smith**. *Evaluating the Timing of Surgical Complications following Cystectomy*. American College of Surgeons Annual Clinical Congress (2016). October 17, 2016. Washington, D.C. October 2016. Podium Presentation.
 39. T Sukhu, J Langston, M Macey, J Lomboy, A Deal, E Kirby, D Viprasakit, M Nielsen, R Pruthi, **A Smith**. *Surgical Equipment Cost Awareness Among Urological Surgeons*. American College of Surgeons Annual Clinical Congress (2016). Washington, D.C. October 2016. Podium Presentation.
 40. J Lomboy, M Macey, T Sukhu, S Stanley, A Deal, M Nielsen, R Pruthi, E Wallen, M Woods, **A Smith**. *Feasibility of Structured Telephone Calls for Symptom Management Following Cystectomy*. American College of Surgeons Annual Clinical Congress (2016). Washington, D.C., October 2016. Poster Presentation.
 41. McKibben M, Kirby EW, Langston J, Nielsen M, Raynor M, Wallen E, **Smith A**, Woods M, Pruthi R. Projecting the Urology Workforce over the Next 20 Years. American Urological Association Annual Meeting, San Diego, CA, May 2016. Poster Presentation.
 42. Sukhu T, Lomboy J, Macey M, Meyer AM, Meng K, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith A**. The association of travel distance to cystectomy on readmission and survival. American Urological Association Annual Meeting, San Diego, CA, May 2016. Poster Presentation.
 43. Macey M, Lomboy J, Sukhu T, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. The Association between Preoperative Leukocytosis and Postoperative Outcomes Following Cystectomy for Bladder Cancer. American Urological Association Annual Meeting, San Diego, CA, May 2016. Poster Presentation.
 44. Macey M, Lomboy J, Sukhu T, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. Evaluating the Timing of Surgical Complications following Nephrectomy. American Urological Association Annual Meeting, San Diego, CA, May 2016. Poster Presentation.
 45. Lomboy J, Macey M, Sukhu T, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. Evaluating the Timing of Surgical Complications following Prostatectomy. American Urological Association Annual Meeting, San Diego,

- CA, May 2016. Poster Presentation. Sukhu T, Lomboy J, Macey M, Meyer AM, Meng K, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith **AB**. The relationship between travel distance to cystectomy and likelihood of readmission. American Society of Clinical Oncology Genitourinary Symposium, Orlando, FL, January 2016, Poster Presentation.
46. Lomboy J, Macey M, Sukhu T, Meyer AM, Meng K, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. The effect of distance to a high-volume center on receipt of treatment for invasive bladder cancer. American Society of Clinical Oncology Genitourinary Symposium, Orlando, FL, January 2016, Poster Presentation.
 47. Johnson DC, Mueller D, Dunn M, **Smith AB**, Woods ME, Wallen EM, Pruthi RS, Nielsen ME. Reducing Decisional Conflict in Men Making Treatment Decisions about Localized Prostate Cancer. Genitourinary Cancers Symposium, Orlando, FL, February 2015, Poster Presentation.
 48. Pruthi N, Johnson DC, Spencer ES, Lyons M, Greene P, Nielsen ME, Pruthi RS, Raynor MC, Wallen EM, Woods ME, **Smith AB**. Feminization of the Workforce in Urologic Oncology: Socioeconomic, Workforce and Quality of Life Issues. Genitourinary Cancers Symposium, Orlando, FL, February 2015, Poster Presentation.
 49. Spencer ES, Lyons M, Greene PS, Meyer AM, Meng K, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith AB**. Understanding the Relationship Between 30- and 90-Day Emergency Room Visits and Readmissions Following Radical Cystectomy. Society of Urologic Oncology (SUO), Bethesda, Maryland, November 3, 2014. Poster Presentation.
 50. Greene PS, Lyons M, Spencer ES, Meyer AM, Meng K, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith AB**. Investigating Patterns of Care for Treatment of Muscle-Invasive Bladder Cancer in a Multi-Payer State Database. Society of Urologic Oncology (SUO), Bethesda, Maryland, November 3, 2014. Poster Presentation.
 51. Lyons M, Crowell K, Spencer ES, Greene P, Woods ME, Wallen EM, Pruthi R, Nielsen ME, Lee CT, **Smith AB**. Functional Outcomes Following Radical Cystectomy in Women with Bladder Cancer: a Systematic Review. Society of Urologic Oncology (SUO), Bethesda, Maryland, November 3, 2014. Poster Presentation.
 52. Vukina J, McKibben M, McBride JA, Matthews J, Pruthi RS, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Identifying Incidence and Risk Factors for VTE Among Radical Prostatectomy Patients for Prostate Cancer. Meeting of the American College of Surgeons. October 2014. Podium Presentation.
 53. J. Abram McBride, Maxim McKibben, Josip Vukina, Jonathan Matthews, Raj Pruthi, Matthew Raynor, Eric Wallen, Michael Woods, Matthew Nielsen, **Angela Smith**. Identifying Incidence and Risk Factors for VTE Among Partial and Radical Nephrectomy Patients for Kidney Cancer. American College of Surgeons Clinical Congress October 2014. Podium Presentation.
 54. Josip Vukina, Maxim McKibben, J. Abram McBride, Jonathan Matthews, Raj Pruthi, Eric Wallen, Michael Woods, Matthew Nielsen, **Angela Smith**. . Identifying Incidence and Risk Factors for VTE Among Radical Prostatectomy Patients for Prostate Cancer. Meeting of the American College of Surgeons. October 2014. Podium Presentation
 55. McKibben MJ, McBride JA, Vukina J, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith A**. Operative Times Predict Length of Stay Following Radical Cystectomy and Nephrectomy. American College of Surgeons Clinical Congress, October 2014. Podium Presentation.
 56. McKibben MJ, Vukina J, McBride JA, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith A**. Predictors of 30-day Readmissions following Radical Cystectomy for Bladder Cancer. Podium: American College of Surgeons Clinical Congress, October 2014. Podium Presentation.
 57. **Smith AB**, Borse MS, Modebe NC, Nielsen ME, Pruthi RS, Johnson DC, Wallen EM, Woods MM, Milowsky MI, Chen RC, Biddle AK. Cost-utility analysis of cystectomy vs. chemo-radiation for treatment of muscle-invasive bladder cancer in the elderly. Poster Presentation. ISPOR 19th Annual International Meeting, May 31- June 4, 2014, Montreal, QC, Canada.

58. McBride JA, Vukina J, McKibben MJ, Matthews J, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. Predictors of 30-day Readmissions following Partial and Radical Nephrectomy for Kidney Cancer. American Urologic Association National Meeting, May 2014. Podium Presentation.
59. Vukina J, McBride JA, McKibben M, Matthews J, Pruthi RS, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Identifying Incidence and Risk Factors for VTE Among Patients Undergoing Cystectomy for Bladder Cancer. Meeting of the American Urologic Association. May 2014. Poster Presentation.
60. Vukina J, McBride JA, McKibben M, Matthews J, Pruthi RS, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Identifying Incidence and Risk Factors for VTE Among Patients Undergoing Cystectomy for Bladder Cancer. Society of Urologic Oncology Meeting. December 2013. Poster Presentation.
61. Vukina J, Pruthi A, McBride JA, McKibben M, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Readability of Online Urologic Oncology Patient Education Materials. Society of Urologic Oncology Meeting. December 2013. Poster Presentation.
62. McBride JA, McKibben MJ, Vukina J, Matthews J, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. Identifying Incidence and Risk Factors for VTE among Partial and Radical Nephrectomy Patients. Society of Urologic Oncology Annual Meeting, December 2013. Poster Presentation.
63. McBride JA, McKibben MJ, Vukina J, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Longer Operative Times Predict Increased Length of Stay Following Cystectomy. Society of Urologic Oncology Annual Meeting, December 2013. Poster Presentation.
64. Johnson DC, Kirby EW, Ferguson JE, Matthews J, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, **Smith AB**. Nutritional predictors for complications following radical cystectomy: an analysis of the American College of Surgeons National Quality Improvement Program. American College of Surgeons Clinical Congress, Washington, DC, October 2013. Podium presentation.
65. Kirby EW, Ferguson JE, Johnson DC, Matthews J, Nielsen ME, Pruthi RS, **Smith AB**, Wallen EM, Woods ME. Metabolic Syndrome as a useful predictor of complications following GU oncologic surgery. American Urologic Association Annual Meeting, San Diego, CA, May 2013. Poster Presentation.
66. Johnson DC, Kirby EW, Ferguson JE, Matthews J, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, **Smith AB**. Utilization of preoperative chemotherapy and associated outcomes after radical cystectomy: An analysis of the American College of Surgeons National Quality Improvement Program. American Urologic Association Annual Meeting, San Diego, CA, May 2013. Moderated poster presentation.
67. Johnson DC, Vukina J, Raynor MC, Woods ME, Wallen EM, Pruthi RS, **Smith AB**, Nielsen ME. Estimating the burden of preoperatively misclassified, surgically removed benign renal masses in the United States: Implications for the current standard of care. American Urologic Association Annual Meeting, San Diego, CA, May 2013. Moderated poster presentation.
68. Johnson DC, Wang N, Kirby EW, Ferguson JE, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Morbidity and mortality following radical cystectomy: An analysis of the American College of Surgeons National Quality Improvement Program. Society of Urologic Oncology Annual Meeting, Bethesda, MD. November 2012. Poster Presentation
69. Ferguson JE, Johnson DC, Kirby EW, Matthews J, Nielsen ME, Pruthi RS, **Smith AB**, Wallen EM, Woods ME. Nutritional predictors for complications following radical cystectomy: An analysis of the American College of Surgeons National Quality Improvement Program. Society of Urologic Oncology Annual Meeting, Bethesda, MD. November 2012. Poster Presentation
70. Kirby EW, Ferguson JE, Johnson DC, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Resident experience as a predictive factor for peri-operative outcomes following radical prostatectomy. Society of Urologic Oncology Annual Meeting, Bethesda, MD. November 2012. Poster Presentation

71. Ferguson JE, Kirby EW, Johnson DC, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Differences in complications between open versus laparoscopic prostatectomy. Society of Urologic Oncology Annual Meeting, Bethesda, MD. November 2012. Poster Presentation.
72. Udell IW, Kurpad R, Raynor MC, Smith AM, Woods ME, Wallen EM, Pruthi RS, Nielsen M. Surveillance Guidelines for Low Grade Non-Invasive Bladder Cancer: A Cost Comparison. American College of Surgeons Clinical Congress. Chicago, IL, October 2012. Podium Presentation.
73. Udell IW, Kurpad R, Smith AB, Woods ME, Wallen EM, Nielsen ME, Pruthi RS. Prospective Randomized Controlled Trial of Robotic Versus Open Radical Cystectomy for Bladder Cancer: Median 3-Year Follow Up Results. American College of Surgeons Clinical Congress. Chicago, IL, October 2012. Podium Presentation.
74. Udell IW, Kurpad R, **Smith AB**, Woods ME, Wallen EM, Nielsen ME, Pruthi RS. Cost Analysis of Robotic-Assisted Radical Cystectomy Versus Open Radical Cystectomy Utilizing a Prospective, Randomized Cohort. American College of Surgeons Clinical Congress. Chicago, IL, October 2012. Podium Presentation.
75. Kurpad R, Fraher E, Neuwahl S, Udell IW, Wallen EM, **Smith AB**, Nielsen ME, Woods ME, Pruthi RS. The Evolving Role and Age Structure of International Medical Graduates on the Urology Workforce in the United States: 1981-2009. American College of Surgeons Clinical Congress. Chicago, IL, October 2012. Podium Presentation.
76. Langston JP, Selph JP, Manvar AM, Ferguson JE, **Smith AB**, Nielsen ME, Wallen EM, Pruthi RS. Re-resecting T1 Bladder Tumors: Single-institution Analysis in a Modern Cohort of Patients. Podium Presentation. American College of Surgeons Clinical Congress. San Francisco, CA, October 2011.
77. Langston JP, Selph JP, Mmeje C, Nunez R, Humphreys M, **Smith AB**, Nielsen ME, Wallen EM, Pruthi RS, Castle E. Robotic Radical Cystectomy: Medium-term Oncologic Follow-up. Podium Presentation. American College of Surgeons Clinical Congress. San Francisco, CA, October 2011.
78. **Smith A**, Sutherland R, Steiner M, Wiener J, Korets R, Liu D, Maizels M. A novel method to teach residents to perform surgery- combining e-learning, computerized enhanced visual learning (CEVL) with simulation to certify mastery of training- a model using newborn clamp circumcision as a simulation. Section on Urology Annual Meeting- American Academy of Pediatrics. Boston, MA. October 15-17, 2011. Podium Presentation.
79. **Smith A**, Coward M, Kim W, Nielsen M, Wallen E, Pruthi R. A Phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary data. American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.
80. **Smith A**, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robot-assisted laparoscopic radical cystectomy: evaluation of the learning curve. American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.
81. **Smith A**, Coward M, Kurpad R, Lal A, Nielsen M, Wallen E, Pruthi R. Cost analysis of robot-assisted laparoscopic radical cystectomy for bladder cancer. American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.
82. **Smith A**, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. The impact of a multidisciplinary approach in the management of urologic malignancies: does it influence diagnostic and treatment decisions? American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.
83. Coward M, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Impact of marital status in patients undergoing radical cystectomy for bladder cancer. American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.
84. Coward M, **Smith A**, Simhan J, Nielsen M, Wallen E, Pruthi R. Racial differences in prostate-specific antigen in hypogonadal men treated with testosterone replacement therapy. American College of Surgeons 95th Annual Clinical Congress. Chicago, IL. October 11-15, 2009. Podium Presentation.

98. **Smith A**, Coward R, Kelly D, Neilsen M, Wallen E, Pruthi R. Evaluation of the incidence of a second urologic malignancy (bladder cancer and kidney cancer) in men with a diagnosis of prostate cancer. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
99. **Smith A**, Coward R, Kurpad R, Nielsen M, Wallen E, Pruthi R. The impact of a multidisciplinary approach in the management of urologic malignancies: does it influence diagnostic and treatment decisions? Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
100. **Smith A**, Coward R, Kelly D, Kurpad R, Nielsen M, Wallen E, Pruthi R. Analysis of the impact of race on bladder cancer treatment and mortality. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
101. Coward R, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy: medium-term clinical and oncologic follow-up. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
102. Coward R, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic anterior pelvic exenteration. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
103. Coward R, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Impact of obesity and adiposity on outcomes of patients undergoing radical cystectomy for bladder cancer. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
104. Coward R, **Smith A**, Kurpad R, Nielsen M, Kim W, Wallen E, Pruthi R. A phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated results and correlative molecular results. Ninth Annual Meeting of the SUO to Discuss Current Topics and Strategies in: Urologic Oncology, Extraordinary Opportunities for Discovery. December 4-6, 2008. Poster presentation.
105. McRackan D, Kouba E, **Smith A**, Wallen E, Pruthi RS. Watchful waiting experience for solid renal masses: insight into the natural history of incidentalomas. American College of Surgeons 92nd Annual Clinical Congress, October 10, 2006. Chicago, Illinois
106. McRackan D, Kouba E, **Smith A**, Wallen E, Pruthi RS. Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association. May 21, 2006. Atlanta, Georgia
107. York, D, **Smith A**, Phillips D, von Allmen, D. The Influence of advanced radiographic imaging on the treatment of pediatric appendicitis.” Scholars.com Scientific Conference. 2005. Oral presentation.
108. Adelberg AM, **Blotzer A (*maiden name)**, Koch G, Moise R, Chescheir N, Wolfe H. Impact of maternal fetal surgery for myelomeningocele on the progression of ventriculomegaly in utero. *AJOG* Conference. 2004. Oral presentation.

Editorials or Letters:

1. Kamat AM, Lobo N, Lerner S, Li R, Matulay J, Palou J, Witjes F, Roupret M, **Smith AB**, Chang S, Shore N, Steinberg G, Dinney C, Lamm D. Reduced Dose Intravesical bacillus Calmette-Guerin: Why It Might Not Matter. *Bladder Cancer* 2021 November, Submitted.

2. *†Bernstein AN, Filippou P, **Smith AB**. Publication Productivity and Bibliometric Profiling: a Potentially Gender Biased Approach. *JAMA Surgery*. 2021 July. ePub ahead of print
3. *†McCloskey H, Hamad J, **Smith AB**. How can we motivate patients with bladder cancer to help themselves? *BJU Int*. 2020 Jun PMID: 32472667
4. McGrath J, **Smith AB**, Williams SB. Invited Editorial: The Complexity of Complications: how do we estimate and target improvements? *Eur Urol*. 2020. PMID: 31727450.
5. **Smith AB**, Solano C. Why Work for Women in Urology? *Urol Columb* 2020;29;180-181
6. **Smith AB** Editorial Comment: Predictors of Compliance With Muscle-Invasive Bladder Cancer Quality Measures and Its Effect on Survival Outcomes. <https://www.practiceupdate.com/content/compliance-with-muscle-invasive-bladder-cancer-quality-measures/111355/65/3/1>. *PracticeUpdate* January 2021
7. *Smelser W, Cooper M Gessner KH, **Smith AB**. Editorial Comment: In Sickness and in Health: Results of the AUA Residents and Fellows Committee Essay Contest. *J Urol* 2020 PMID 32501123
8. **Smith AB**. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated With Atezolizumab. <https://www.practiceupdate.com/content/concomitant-antibiotic-use-and-survival-in-urothelial-carcinoma-treated-with-atezolizumab/103882/65/3/1>. *PracticeUpdate*. August 2020 PMID 32660748
9. *†Talwar R, **Smith AB**. Editorial Comment, Gender Representation among Plenary Panel Speakers at the American Urological Association Annual Meeting. *Urology*, 2021 Apr; 150:58. PMID 33812548.
10. *†Nikas, C, **Smith AB**. Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage. *Eur Urol*. 2020 June; PMID: 32532515
11. *Smelser W, Cooper M, Gessner K, **Smith AB**. Standing Together: Going above and beyond for one of our own; The 2020 American Urological Association Residents and Fellows Essay Contest. *J Urol* 2020 May; PMID 32396048
12. *†Hamad J, McCloskey H, Milowsky MI, Royce T, **Smith AB**. Bladder preservation in muscle invasive bladder cancer: a comprehensive review. *International Brazilian Journal of Urology* 2020 Mar-Apr;46(2):169-184. PMID 31962624
13. *†McCloskey H, Hamad J, **Smith AB**. Modifiable Lifestyle Behaviors and Their Impact on Health-Related Quality of Life of Bladder Cancer Survivors. “How can we motivate bladder cancer patients to help themselves?” *BJU-2019-1416.R1* 2020 Jan PMID 32472667
14. McGrath J, **Smith AB**, Williams SB. The Complexity of Complications: “How do we estimate and target improvements?” *Eur Urol* 2019 Nov PMID 31727450
15. *†Filippou P, **Smith AB**. Editorial Comment: on Development of a Goal Elicitation Measure to Support Choice about Urinary Diversion by Patients with Bladder Cancer.; *J Urol*. 2019 Jul; 202(1);89. PMID 30958753.
16. **Smith AB**. Editorial Comment on The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy. *J Urol* 2019 May;210(5):908. PMID 30822198.
17. *†Filippou P, **Smith AB**. “A new horizon for bladder preservation in muscle invasive bladder cancer”. *BJUI* 2019; <https://doi.org/10.1111/bju.14786> PMID 31321869
18. **Smith AB**. Editorial Comment on “Natural history and predictors of parastomal hernia after robot-assisted radical cystectomy and ileal conduit urinary diversion.” *Journal of Urology* 2018 Mar; 199(3): 773. PMID 28890392

19. *Linscott JA, **Smith AB**, Sammon JD. Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. *Eur Urol* 2018 Apr;73(4):e102-e103. PMID: 29129400
20. **Smith AB**. Editorial Comment on "Increased use of cystectomy in patients 75 and older: a contemporary analysis of survival and perioperative outcomes from the National Cancer Data Base." *Urology*. 2017 Feb; 100:78. PMID: 27871744.
21. **Smith AB**. Editorial comment. Anticipating the unintended consequences of closing the door on physician self-referral. *Journal of Urology*. 2016 Aug; 196(2):450. PMID: 27125542.
22. *†Spencer ES, **Smith AB**. Exploring the 3 A's of cystectomy access to care for muscle-invasive bladder cancer. *Urol Oncol*. 2015 Mar; 33(3): 105-7. PMID: 25579780.
23. **Smith AB**, Milowsky MI. Is Extending Surveillance Guidelines for Renal Cell Carcinoma Without Understanding Patient Outcomes Putting the Cart Before the Horse? *Journal of Clinical Oncology*. 2014 Dec; 32(36):4031-2. PMID: 25403216.
24. **Smith AB**. Editorial comment. Interobserver variability of Clavien-Dindo scoring in urology. *Int J Urol*. 2014 Dec;21(12): 1279. PMID: 25099382.
25. *Johnson DC, **Smith AB**. Editorial Comment. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. 2014 Aug; 84(2): 378-9. PMID: 24958478.
26. **Smith AB**. Editorial comment. Measuring and predicting prostate cancer related quality of life changes using EPIC for Clinical Practice. *J Urol*. 2014 Mar; 191(3):638-645. PMID: 24291118.
27. **Smith AB**. Editorial comment. Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. *Int J Urol*. 2014 Feb; 21(2): 149-150.. PMID: 23944847.
28. **Smith AB**, Pruthi RS. Phase II study of everolimus in metastatic urothelial cancer. *BJU Int*. 2013 Aug; 112(4):427-8. PMID: 23879903.
29. Pruthi RS, **Smith AM**. Editorial comment. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. *Journal of Urology*. 2011 Jan; 185(1):96. Epub 2010 Nov 12. PMID 21074801.
30. **Smith AB**, Pruthi RS. Editorial comment. Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population study. *Urology*. 2010 Feb; 75(2):398. PMID: 20152492.

Products of Interdisciplinary Research

- NOTE: products of interdisciplinary research are indicated in original refereed papers/articles/editorials section above using the ‡ symbol to avoid duplication in this section
- My research has evolved from retrospective analyses during training to a research program that hinges on interdisciplinary research, with co-investigators and co-authors from a variety of fields:
 - Epidemiology
 - Health Policy & Management
 - Dissemination & Implementation
 - Medical Oncology
 - Radiation Oncology
 - Biostatistics
 - Radiology
 - Immunology

Digital and Other Novel Forms of Scholarship

1. “Vacation”, Operate with Zen Podcast, recorded September 23, 2021. <https://podcasts.apple.com/us/podcast/6-discussion-integrated-habits-with-dr-angela-smith/id1579495428?i=1000530856931>
2. “Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer”. PracticeUpdate Website, Invited Guest, September 15, 2021. <https://www.practiceupdate.com/content/prognostic-implications-of-treatment-delays-for-non-muscle-invasive-bladder-cancer/122688/65/3/1>
3. “Perioperative Optimization of Patients Receiving Radical Cystectomy,” BackTable Podcast, invited guest, July 11, 2021. <https://www.backtable.com/urology-podcast/18/perioperative-optimization-for-radical-cystectomy-patients-part-2>
4. “Tips for Promoting Your Work in Urology Online,” Episode 190, AUA Inside Tract Podcast, June 2021.
5. “Integrated Habits with Dr. Angela Smith,” Operate with Zen podcast, invited guest, July 1, 2021. <https://operatewithzen.buzzsprout.com/>
6. “Deintensification of Management of Low-Risk NMIBC. Dr. Angela Smith and Ashish Kamat Discuss the Importance of Distinguishing between low-risk vs low-grade NMIBC and the need for Biomarkers to Improve or to Potentially avoid Cystoscopy” *UroToday.com* April 25, 2021 <https://www.urotoday.com/video-lectures/asco-gu-2021-bladder-and-kidney-cancer/video/2090-deintensification-of-management-of-low-risk-nmibc-angela-smith.html>
7. “LUGPA Crossfire in UTUC,” PlatformQ, featured speaker, https://www.urocarelive.com/app/signup/081820_UCL_LUGPA_UTUC_CME_Reg/formPage/
8. Medscape Bladder Cancer Decision Point Series, invited speaker, March 2020, <https://decisionpoint.medscape.com/urology>
9. “My Experience as an AUA Assistant Secretary with Dr. Angela Smith” *AUA Inside Tract Podcast*, invited speaker, <https://www.auanet.org/podcast/my-experience-as-an-aua-assistant-secretary-with-dr-angela-smith>
10. “Dr. Angela B. Smith on what constitutes a patient-centered clinical trial” *Urology Times*, December 3, 2020 <https://www.urologytimes.com/view/what-constitutes-a-patient-centered-clinical-trial>
11. “Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC” *Urology Times*, May 20, 2020 <https://www.urologytimes.com/genitourinary-cancers/dr-angela-smith-discusses-recent-fda-approval-jelmyto-low-grade-utuc>
12. Expert co-host, *AUA Inside Tract Podcast*, January 2020
13. “Financial Toxicity Among Bladder Cancer Patients” *Urology Times* November 2019
14. Expert co-host; “Bladder Cancer” Men’s Health Show *SiriusXM*; October 16, 2019
15. Expert co-host; “Bladder Cancer” documentary segment slated for airing nationally as part of a one-hour documentary special for the Exploration Health series on the Public Television Network (PBS Member Stations); 2018
16. AUA Press Session: Kathryn E. Hacker MD PhD, **Angela B. Smith MD MS**, Matthew E. Nielsen MD MS. Post-operative opioid prescribing in urology: are we contributing to the national crisis?; 2018
17. AUA Webinar, Complex Patients in Bladder Cancer, "Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer Webinar #4," July 20, July 25, 2017

18. “Chemotherapy Use for Upper Tract Urothelial Carcinoma Increasing.” Renal and Urology News; published 2017.
19. **Smith A.** Lymph Node Fluorescence during Robot-Assisted Radical Prostatectomy with Indocyanine Green: Prospective Dosing Analysis. Practice Update website. Available at: <http://www.practiceupdate.com/content/lymph-node-fluorescence-during-robot-assisted-radical-prostatectomy-with-indocyanine-green/56961/65/3/1>. Accessed September 20, 2017.
20. Eggener, Scott (Ed.), Quek M, **Smith A**, Woods M. “Adrenal Neoplasms.” American Urological Association Core Curriculum. 29 Dec. 2016. Web. 1 Mar 2017. https://www.auanet.org/university/core_topic.cfm?coreid=80
21. “Bladder Cancer.” Angela B. Smith. Urology Care Foundation Blog; published November 2016. <http://www.urologyhealth.org/careblog/what-to-know-about-bladder-cancer>
22. “Spotting Bladder Cancer: 5 things women need to know.” Angela B. Smith. USA News insert; also published on Media Planet. September 15, 2015. <http://www.futureofpersonalhealth.com/prevention-and-treatment/spotting-bladder-cancer-5-things-women-need-to-know>
23. “Nutritional predictors of complications following radical cystectomy ‘Beyond the Abstract’.” David C. Johnson, Angela B. Smith. UroToday. March 31, 2015. http://urotoday.com/index.php?Itemid=813&option=com_content&view=article&catid=1160&id=79485
24. “Current guidelines miss one-third of RCC Recurrences.” Cancer Network. Reported by Leah Lawrence. November 28, 2014. <http://www.cancernetwork.com/renal-cell-carcinoma/current-guidelines-miss-one-third-rcc-recurrences>
25. “Renal cell carcinoma guidelines miss one-third of recurrences.” November 25, 2014. The Oncology Report. Reported by Bianca Nogrady. <http://www.oncologypractice.com/the-oncology-report/news/news/single-article/renal-cell-carcinoma-guidelines-miss-one-third-of-recurrences/e645f481e299d62a9ecc30151725ac0d.html>
26. **Smith A**, Quek M, Woods M (2014). “Adrenal Neoplasms” in American Urological Association Core Curriculum. (<https://www.auanet.org/university/search.cfm>)
27. “Poor Nutrition is risk factor for patients who have cystectomy.” December/January 2013/2014. *The Triangle Physician*.
28. “Bladder cancer chemo does not raise surgery complication risks.” March 26, 2014. Renal & Urology News. reported by Jody A. Charnow. <http://www.renalandurologynews.com/bladder-cancer-chemo-does-not-raise-surgery-complication-risks/article/339843/>
29. “Sarcopenia predicts cystectomy complications in women.” January 28, 2014. Nature Reviews Oncology. Research Highlight. Noted on Pubmed: PMID 24473419 <http://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2014.14.html>
30. “Nutritional status affects post-cystectomy outcomes.” Urology Times. January 22, 2014. <http://urologytimes.modernmedicine.com/urology-times/news/nutritional-status-affects-post-cystectomy-outcomes>
31. “Low serum albumin before surgery is predictor of complications following radical cystectomy.” January 15, 2014. Reported by Beth Fand Incollingo. Press release: OncLive <http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Low-Serum-Albumin-Before-Surgery-is-Predictor-of-Complications-Following-Radical-Cystectomy>
32. “Patients with poor nutritional status before bladder cancer operation have a higher risk of postoperative complications.” October 16, 2013. Press release: http://www.eurekalert.org/pub_releases/2013-10/uonc-

33. American College of Surgeons Clinical Congress, McCormick Place Convention Center, Chicago, IL “Meet the Press,” “Anticancer drug improves survival and treatment for patients with advanced bladder cancer. October 13, 2009. Webcast: <http://www.facs.org/clincon2009/press/pressconf.html>. Press release: <http://www.facs.org/clincon2009/press/smith.html>.
34. “Phase 2 study shows benefit of erlotinib in invasive bladder cancer.” Medscape Medical News, Kathleen Loudon, Chicago, IL, October 16, 2009, <http://www.medscape.com/viewarticle/710694>.

Refereed Unpublished Oral Presentations and/or Abstracts

1. Lerner S, Svatek R, Sachse K, Bross P, Shore N, Hahn N, Jaigirdar A, Bloomquist E, Brewer J, O’Donnell M, Stienber G, Kamat A, Ribal M, Kluetz P, Viviano C, Galsky M, Oliver R, Agrawal S, Black P, Al-Ahmadie, H, Pohar K, Dinney C, Feng Z, Downs T, Porten S, **Smith AB**, Agarwal N, Bangs R, Bhatnagar V, Brothers K, Psutka S. Patient-Focused Drug Development: Capturing High Quality Experience Data. Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC) November 18-19, 2021; Virtual due to Covid.
2. Parisse T, Hamad J, Mohan C, Basak R, Kent E, **Smith AB**. Time-To-Treatment After Cancer Diagnosis and the Patient Experience With Care: A Seer-CAHPS Study. The 85th Annual Meeting of the Southeastern Section of the American Urological Association; April 23-24, 2021; Virtual due to Covid.
3. Gurjar M, Osterman C, Muss H, Bjurlin M, Tan HJ, Nielsen M, Wallen E, Aleixo G, Yu H, **Smith AB**. Evaluating the Prevalence of and Relationship Between Malnutrition and Sarcopenia in Patients with Bladder Cancer Undergoing Cystectomy. The 85th Annual Meeting of the Southeastern Section of the American Urological Association; April 23-24, 2021; Virtual due to Covid.
4. Parisse T, Reines K, Basak R, Mueller, **Smith AB**. Patient Perception of Repeat Turbts and Chemoablation for Bladder Cancer. The 85th Annual Meeting of the Southeastern Section of the American Urological Association; April 23-24, 2021; Virtual due to Covid.
5. Ehlers M, Gore J, Chisolm S, Deal A, Sachse, K, Lipman R, Patient Survey Network, **Smith AB**. Assessment of Financial Toxicity in Bladder Cancer Patients Using a Validated Questionnaire. The 83rd Annual Meeting of the Southeastern Section of the American Urological Association; March 13 - 16, 2019; Phoenix, AZ.
6. Filippou P, Hacker KE, Deal AM, Mahajan S, Wallen EM, Pruthi RS, Wallen EM, Tan HJ, **Smith AB**. Gender bias in letters of recommendation for urology resident applicants. SES-AUA Conference, Orlando, FL, March 2018.
7. McCormick B, Deal A, Filippou P, Narang G, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith A**. Trends in the Use of Chemotherapy for Treatment of Upper Tract Urothelial Carcinoma Using the National Cancer Database. American Urologic Association Southeastern Annual Sectional Meeting, Austin, Texas. March 2017. Poster Presentation.
8. McCormick B, Kurpad R, Lomboy J, Fifer L, **Smith A**, Nielsen M, Woods M, Wallen E, Pruthi R, Raynor M. Robot-assisted ureteral reconstruction distal to the UPJ: A single institution experience of 99 patients. American Urologic Association Southeastern Section Annual Meeting, Austin, Texas. March 2016. Poster Presentation.
9. Kurpad R, Lomboy J, Fifer L, McCormick B, **Smith A**, Nielsen M, Woods M, Wallen E, Pruthi R, Raynor M. Robot Assisted Ureteral Reconstruction After Iatrogenic Injury: A Single Institution Experience of 41 Patients. American Urologic Association Southeastern Section Annual Meeting, Austin, Texas. March 2016. Poster Presentation.
10. Filippou P, Deal A, Narang G, McCormick B, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith A**. Trends in

Patient Refusal of Neo-Adjuvant Chemotherapy for Muscle Invasive Bladder Cancer. American Urologic Association Southeastern Annual Sectional Meeting, Austin, Texas. March 2017. Poster Presentation.

11. Casilla–Lennon M, Cho S, Deal A, Benson J, Narang G, Filippou P, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith A**. The Relationship Between Financial Toxicity and Quality of Life Among Bladder Cancer Patients. American Urologic Association Southeastern Annual Sectional Meeting, Austin, Texas. March 2017. Poster Presentation.
12. McKibben M, Filippou P, McCormick B, Narang G, Crowell K, Borawski K. Use of Botulinum Toxin A in Refractory Overactive Bladder in Parkinson’s Disease: A Systematic Review. American Urologic Association Southeastern Annual Sectional Meeting, Austin, Texas. March 2017. Poster Presentation.
13. Casilla–Lennon M, Cho S, Deal A, Benson J, Narang G, Filippou P, McCormick B, Pruthi R, Wallen E, Woods M, Nielsen ME, **Smith A**. Financial Toxicity Prevalence and Delay in Care Among Bladder Cancer Patients. American Urologic Association Southeastern Annual Sectional Meeting, Austin, Texas. March 2017. Podium Presentation.
14. Ferguson J, Deal A, Smith AB, Nielsen ME, Woods ME. Contemporary survival trends in penile cancer. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
15. Lomboy J, Macey M, Sukhu T, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. Evaluating the timing of surgical complications following prostatectomy. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
16. Macey M, Sukhu T, Lomboy J, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M and **Smith A**. The association between preoperative leukocytosis and postoperative outcomes following prostatectomy for prostate cancer. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
17. Lomboy J, Deal A, **Smith A**, Woods M, Wallen E, Nielsen M, Raynor M. Predictors of overall survival in patients with stage i renal cell carcinoma. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
18. Lomboy J, Macey M, Sukhu T, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. The relationship between travel distance to cystectomy and likelihood of readmission. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
19. McKibben M, Nielsen M, Pruthi R, Raynor M, **Smith A**, Woods M. Robot-assisted nephroureterectomy for treatment of upper tract urothelial cell carcinoma. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
20. Lomboy J, Deal A, **Smith A**, Woods M, Wallen E, Nielsen M, Raynor M. Clinical predictors of radical or partial nephrectomy for stage i renal cell carcinoma in younger patients: analysis of the national cancer data base. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
21. Lomboy J, Macey M, Sukhu T, Deal A, Raynor M, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. The association between preoperative leukocytosis and postoperative outcomes following nephrectomy for kidney cancer. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
22. Lomboy J, Deal A, **Smith A**, Woods M, Wallen E, Nielsen M, Raynor M. Trends in diagnosis, management, and overall survival of renal cell carcinoma: analysis of the national cancer data base. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
23. Sukhu T, Lomboy J, Macey M, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. Evaluating the timing of surgical complications following cystectomy. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.

24. Macey M, Sukhu T, Lomboy J, Stanley S, Deal A, Mueller D, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith A**. Understanding the trajectory of symptoms and functioning in the 90-day cystectomy period. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Podium Presentation.
25. Langston J, Macey M, Sukhu T, Lomboy J, Deal A, Kirby EW, Viprakasit D, Nielsen M, Pruthi R, **Smith A**. Surgical equipment cost awareness among urological surgeons. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
26. Langston J, Schultz H, Sukhu T, Lomboy J, Macey M, Orcutt V, Kirby EW, Nielsen M, **Smith A**, Pruthi R. Advanced practice providers in U.S. urology. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
27. Sukhu T, Lomboy J, Macey M, Meyer AM, Meng K, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith A**. The effect of distance to a high-volume center on receipt of treatment for invasive bladder cancer. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
28. Sukhu T, Lomboy J, Macey M, Deal A, Wallen E, Woods M, Pruthi R, Nielsen M, **Smith A**. The association between preoperative leukocytosis and postoperative outcomes following cystectomy for bladder cancer. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
29. Lomboy J, Macey M, Sukhu T, Stanley S, Deal A, Mueller D, Nielsen M, Pruthi R, Wallen E, Woods M, **Smith A**. Feasibility of structured telephone calls for symptom management following cystectomy. Southeast Section of American Urological Association, Nashville, TN, March 18, 2016. Poster Presentation.
30. Spencer ES, Lyons M, Greene PS, Meyer AM, Meng K, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Understanding the Relationship Between 30- and 90- day Emergency Room Visits and Readmissions Following Radical Cystectomy. Southeast Section of American Urological Association, Savannah, Georgia, March 19, 2015. Poster Presentation
31. Spencer ES, Pruthi N, Lyons M, Greene PS, Meyer AM, Meng K, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. The Feminization of the Workforce in Urology: Economic, Workforce, and Quality of Life Issues. South East Section American Urological Association, Savannah, Georgia, March 19, 2015. Poster Presentation
32. Greene PS, Pruthi N, Spencer ES, Lyons M, Greene PS, Meyer AM, Meng K, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. Private Practice, Academics or Employed: Does Employment Status Impact Work, Income, and Job Satisfaction? Southeast Section of the American Urological Association, Savannah, Georgia, March 19, 2015. Poster Presentation.
33. Lyons M, Greene PS, Pruthi N, Spencer ES, Meyer AM, Meng K, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. Job Satisfaction in Urology: the Influence of Demographic, Economic, and Workload Factors. Southeast Section of the American Urological Association, Savannah, Georgia, March 19, 2015. Poster Presentation.
34. McKibben M, Rose T, Lyons M, Deal A, Spencer ES, Greene PS, Nielsen ME, Pruthi R, Wallen E, Milowsky M, **Smith AB**. Trends and Predictors of Palliative Care Services and Mortality in the Treatment of Advanced Bladder Cancer. Southeast Section of American Urological Association, Savannah, Georgia, March 20, 2015. Poster Presentation.
35. Lyons M, Greene PS, Pruthi N, Spencer ES, Meyer AM, Meng K, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. The Impact of a Fellowship and Career Focus in Urology on Socioeconomic, Workforce and Quality of Life Issues South East Section American Urological Association, Savannah, Georgia, March 19, 2015. Poster Presentation.
36. Johnson DC, Matthews J, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, **Smith AB**. Utilization of Neoadjuvant Chemotherapy and Associated Outcomes After Radical Cystectomy: Analysis of the American

College of Surgeons National Quality Improvement Program. Inaugural George F. Sheldon Resident Research Symposium, Chapel Hill, NC. May 2014. Podium presentation.

37. McBride JA, McKibben MJ, Vukina J, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Longer Operative Times Predict Increased Length of Stay Following Cystectomy. Southeast Section American Urologic Association Annual Meeting, March 2014. Podium Presentation.
38. McBride JA, McKibben MJ, Vukina J, Matthews J, Pruthi R, Raynor M, Wallen E, Woods M, Nielsen M, **Smith AB**. Identifying Incidence and Risk Factors for VTE among Partial and Radical Nephrectomy Patients. Southeast Section American Urologic Association Annual Meeting, March 2014. Poster Presentation.
39. Pruthi A, Vukina J, McBride JA, McKibben MJ, Raynor M, Woods M, Nielsen M, Wallen E, **Smith AB**. Readability of Online Urologic Oncology Patient Education Materials. Southeast Section American Urologic Association Annual Meeting, March 2014. Poster Presentation.
40. Vukina J, McBride JA, McKibben M, Matthews J, Pruthi RS, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Identifying Incidence and Risk Factors for VTE Among Patients Undergoing Cystectomy for Bladder Cancer. Meeting of the Southeast Section of the American Urologic Association. March 2014. Podium Presentation.
41. Vukina J, McBride JA, McKibben M, Matthews J, Pruthi RS, Wallen EM, Woods ME, Nielsen ME, **Smith AB**. Longer Operative Times Predict Increased Length of Stay Following Prostatectomy for Prostate Cancer. Meeting of the Southeast Section of the American Urologic Association. March 2014. Podium Presentation.
42. McKibben MJ, Vukina J, McBride JA, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Identifying Incidence and Risk Factors for VTE among Radical Prostatectomy Patients for Prostate Cancer. Southeast Section American Urological Association Annual Meeting, Orlando, FL, March 2014. Poster Presentation.
43. McKibben MJ, Vukina J, McBride JA, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Predictors of 30-day Readmissions following Radical Cystectomy for Bladder Cancer. Southeast Section American Urological Association Annual Meeting, Orlando, FL, March 2014. Poster Presentation.
44. McKibben MJ, Vukina J, McBride JA, Matthews J, Pruthi R, Wallen E, Woods M, Nielsen M, **Smith AB**. Sarcopenia as a Predictor for Complications and Survival Following Radical Cystectomy among Women. Southeast Section American Urological Association Annual Meeting, Orlando, FL, March 2014. Poster Presentation.
45. Kirby EW, Johnson D, Ferguson JE, Manvar A, Woods ME, Wallen EM, Raynor M, Nielsen M, Pruthi R. **Smith AB**. The short-term impact of prostate biopsy on patients' erectile function. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Podium presentation.
46. Kirby EW, Johnson D, Ferguson JE, **Smith AB**, Woods ME, Wallen EM, Raynor M, Nielsen M, Pruthi R. Projection models evaluating the future supply of urologists in the United States. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
47. Kirby EW, Ferguson JE, Johnson D, Manvar A, **Smith AB**, Woods ME, Wallen EM, Raynor M, Nielsen M, Pruthi R. Use and perceptions of information obtained from the internet: Analysis of urologic oncology patients. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
48. Hester A, Ferguson JE, Johnson DC, Kirby EW, **Smith AB**, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, Raynor MC. The effect of hypogonadism on PSA, erectile function, and surgical pathology in patients with prostate cancer. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
49. Kirby EW, Ferguson JE, Johnson DC, Matthews J, Nielsen ME, Pruthi RS, **Smith AB**, Wallen EM, Woods ME.

- Metabolic Syndrome as a useful predictor of complications following GU oncologic surgery. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
50. Kirby EW, Ferguson JE, Johnson DC, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Resident experience as a predictive factor for peri-operative outcomes following radical prostatectomy. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
 51. Langston J, Kirby EW, Ferguson JE, Johnson DC, **Smith AB**, Viprakasit D, Raynor M, Woods ME, Wallen EM, Nielsen M, Pruthi RS. Economic impact of training and career choices in urologic surgery. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Poster Presentation.
 52. Johnson DC, Kirby EW, Ferguson JE, **Smith AB**, Woods ME, Raynor MC, Wallen EM, Fifer GL, Pruthi RS, Nielsen ME. Estimating the burden of preoperatively misclassified, surgically removed benign renal masses in the United States: implications for the current standard of care. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Podium presentation.
 53. Johnson DC, Kirby EW, Ferguson JE, Matthews J, Nielsen ME, Pruthi RS, Woods ME, Raynor MC, Wallen EM, **Smith AB**. Utilization of preoperative chemotherapy and associated outcomes after radical cystectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013. Podium presentation.
 54. Johnson DC, Kirby EW, Ferguson JE, Calvo B, Meyers M, Stitzenberg K, Kim H, **Smith AB**, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, Raynor MC. Nephrostomy placement after surgical resection of locally recurrent colorectal cancer: An assessment of risk factors. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013.
 55. Johnson DC, Kirby EW, Ferguson JE, Calvo B, Meyers M, Stitzenberg K, Kim H, **Smith AB**, Woods ME, Nielsen ME, Wallen EM, Pruthi RS, Raynor MC. Urologic involvement in surgical resection of recurrent colorectal cancer. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013.
 56. Johnson DC, Ferguson JE, Kirby EW, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Diffusion of laparoscopy and differences in complications compared to open radical nephrectomy. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013.
 57. Johnson DC, Ferguson JE, Kirby EW, Matthews J, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, **Smith AB**. Differences in complications and associated risk factors in open versus laparoscopic partial nephrectomy. Southeastern Section of the American Urologic Association Annual Meeting, Williamsburg, VA, March 2013.
 58. **Smith A**, McKim S, Simopoulos E, Nix J, Raynor M, Nielsen M, Wallen E, Pruthi R. Prospective, randomized trial of robotic versus open radical cystectomy for bladder cancer: peri-operative and pathological results. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
 59. **Smith A**, Raynor M, Amling C, Busby JE, Castle E, Davis R, Thomas R, Nielsen M, Wallen E, Pruthi R. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: peri-operative outcomes in 227 patients. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
 60. **Smith A**, Raynor M, Amling C, Busby JE, Castle E, Davis R, Thomas R, Nielsen M, Wallen E, Pruthi R. Complications associated with robotic radical cystectomy for bladder cancer: a multi-institutional analysis. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
 61. McKim S, Simopoulos E, **Smith A**, Raynor M, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic intracorporeal urinary diversion. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-

24, 2010. Oral Presentation.

62. McKim S, Simopoulos E, **Smith A**, Raynor M, Nielsen M, Wallen E, Pruthi R. Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in the elderly. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
63. Simopoulos E, McKim S, Waldorf B, **Smith A**, Nielsen M, Wallen E, Pruthi R. Long-term follow-up of patients initially managed with active surveillance for solid renal masses. Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
64. Simopoulos E, McKim S, Dray E, **Smith A**, Nielsen M, Wallen E, Pruthi R. Does age affect presentation and outcomes in patients undergoing radical cystectomy for bladder cancer? Southeastern Section of the AUA 74th Annual Meeting. Miami, FL. March 21-24, 2010. Oral Presentation.
65. **Smith A**, Doak H, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
66. **Smith A**, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. Does the time of day or day of the week affect outcomes after robotic-assisted laparoscopic radical prostatectomy? Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
67. **Smith A**, Johnson D, Kelly D, Coward M, Pruthi R, Wallen E. Impact of hospital type on surgical treatment for kidney cancer: recent trends. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
68. **Smith A**, Coward M, Lal A, Kurpad R, Nielsen M, Wallen E, Pruthi R. Cost analysis of robotic-assisted laparoscopic radical cystectomy for bladder cancer. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
69. **Smith A**, Coward M, Kim W, Grigson G, Kurpad R, Wallen E, Nielsen M, Pruthi R. A Phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
70. Coward M, Kelly D, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. An analysis of the impact of race on bladder cancer treatment and mortality. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
71. **Smith A**, Coward M, Nielsen M, Wallen E, Pruthi R. Video: Robotic-assisted laparoscopic anterior pelvic exenteration for bladder cancer in the female. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
72. Coward M, **Smith A**, Nielsen M, Wallen E, Pruthi R. Video: Robotic-assisted laparoscopic pelvic lymphadenectomy. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
73. Coward M, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Impact of obesity on operative, pathologic, and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
74. Coward M, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy for bladder cancer: experience in 85 patients and comparison to an open cohort. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Oral Presentation.
75. Belsante J, Coward M, **Smith A**, Kurpad R, Wallen E, Pruthi R. Preliminary experience with prostate-sparing cystectomy for urothelial carcinoma of the bladder. Southeastern Section of the AUA 73rd Annual Meeting.

Mobile, AL. March 26-29, 2009. Oral Presentation.

76. Coward M, **Smith A**, Kurpad R, Nielsen M, Wallen E, Pruthi R. Achieving complete success after robotic radical prostatectomy: is the trifecta in reach? Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Poster Presentation.
77. Belsante J, Coward M, **Smith A**, Kurpad R, Wallen E, Pruthi R. Clinical outcomes of a stapled ileal neobladder after radical cystectomy for bladder cancer. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Poster Presentation.
78. **Smith A**, Coward M, Kurpad R, Shingleton B, Nielsen M, Wallen E, Pruthi R. Robotic-assisted laparoscopic radical cystectomy: evaluation of the learning curve. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Poster Presentation.
79. **Smith A**, Coward M, Kurpad R, Nielsen M, Wallen E, Pruthi R. The impact of a multidisciplinary approach in the management of bladder cancer. Southeastern Section of the AUA 73rd Annual Meeting. Mobile, AL. March 26-29, 2009. Poster Presentation.
80. **Smith A**, Kouba E, Gunn K, Wallen E, Pruthi R. Gender-dependent associations between body composition in patients with renal cell carcinoma. 71st AUA Southeastern Section Annual Meeting. March 8, 2007. Oral presentation.
81. **Smith A**, Kouba E, Gunn K, Wallen E, Pruthi R. Impact of surgical treatment of renal carcinoma on renal function and blood pressure: a race- and age-dependent association. 71st AUA Southeastern Section Annual Meeting. March 8, 2007. Oral presentation.
82. Kouba E, **Smith A**, Wallen E, Pruthi R. Characterization of pT3A renal carcinoma in tumors less than 4.0 cm in size. 71st AUA Southeastern Section Annual Meeting. March 8, 2007. Poster presentation.
83. Kouba E, Smith A, McRackan D, Wallen E, Pruthi R. Expectant management of small renal masses and results of delayed intervention. 47th Annual Student Research Forum. April, 2006.
84. McRackan D, Kouba E, **Smith A**, Wallen E, Pruthi RS. Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
85. **Smith A**. LGBTQ youth support in the triangle.” University of North Carolina School of Medicine Community Service Day, February 19, 2005. Oral presentation.

Other - In Press Abstract Presentation:

1. Stover AM, Kurtzman R*, **Smith AB**, Chung AE. (December, 2021). Implementing a clinic-wide intervention in primary care via the electronic health record: Unmet training needs of the primary care team and rollout team. Presentation under review at the AcademyHealth Dissemination and Implementation conference, virtual due to the pandemic. 1 page.

TEACHING ACTIVITIES

Lectures

Students

- “Urologic Malignancies,” SOM Medical Student annual Renal Block, 2018—2021
- “Patient Reported Outcomes and Patient Engagement”. HPM 794 – Patient-Reported Outcomes Measurement and Application in Healthcare Research and Practice. UNC-Chapel Hill: UNC-Chapel Hill, Invited Lecturer, February 9, 2021

Residents/Fellows

- “Urinary Diversions: Techniques and Complications” Gynecologic Oncology Conference, January 2022
- “Muscle Invasive Bladder Cancer” Urology Resident Indications Conference, September 2021
- “Finance for Residents” Urology Resident Conference, January 2020
- “How to Write: A guide to academic writing” Urology Resident Conference, September 2019
- “Basic Statistics,” UNC Urology Indications Conference, September 2016

Grand Rounds

- “Wellness and Time Efficiency.” UNC Urology Grand Rounds, September 2021.
- “Oncology Clinical Research Update.” UNC Urology Grand Rounds, September 2020.
- “How to Write: A Guide to Academic Writing.” UNC Urology Grand Rounds, May 2018.
- “Perioperative Intravesical Gemcitabine.” UNC Urology Grand Rounds, March 2018.
- Quarterly Department Research Meeting. UNC Urology Grand Rounds, March 2018.
- Quarterly Department Research Meeting. UNC Urology Grand Rounds, January 2017.
- “Communication and Time Management” UNC Urology Grand Rounds, October 2016.
- “How to Write” Workshop. UNC Urology Grand Rounds, April 2015
- Hematuria and Bladder Cancer Evaluation and Management. WakeMed Internal Medicine Grand Rounds, March 2015
- Navigating secondary data analysis and large datasets. UNC Urology Grand Rounds, June 2014
- Statistics for Surgeons, Part 3. “Multivariable Analysis,” UNC Urology Grand Rounds, April 2013.
- Statistics for Surgeons, Part 2. “Bivariable Analysis,” UNC Urology Grand Rounds, March 2013.
- Statistics for Surgeons, Part 1. “Univariable Analysis and p-values,” UNC Urology Grand Rounds, February 2013.
- “Radical Cystectomy for Bladder Cancer.” UNC Radiation Oncology Grand Rounds, January 2013.
- “Focal Therapy for Localized Prostate Cancer.” Carolinas Medical Center Urology Grand Rounds, May 2011.

Continuing Education Lecture Within UNC

- “Patient Engagement in Bladder Cancer,” Floyd A. Fried Symposium: Advances in Urology, Chapel Hill, North Carolina, June 19, 2021.
- “Patient Engagement and Translational Patient-Centered Outcomes Research in Bladder Cancer”. Cancer Outcomes Research Program Weekly Breakfast Seminar: Chapel Hill, NC (Virtual) Invited Speaker, November 3, 2020
- “Looking Ahead: Advances in the Treatment of Non-Invasive Urothelial Cancer” 14th Annual Floyd A. Fried Symposium: Advances in Urology, Chapel Hill, North Carolina, June 24, 2016
- “Change in HRQOL from before to after bladder cancer diagnosis.” Cancer Outcomes Research Program Weekly Breakfast Seminar: Chapel Hill, NC Invited Speaker, 2016
- “Non-muscle invasive bladder cancer: diagnostic and treatment strategies.” UNC Cancer Network Telehealth Medical Lecture, invited speaker, May 27, 2015
- “Assessment of pre-operative risk in the geriatric urologic patient.” 11th Annual Landes Symposium: Advances in Urology, Chapel Hill, North Carolina, June 21, 2013

Continuing Education Lecture Outside UNC

International

1. Invited Speaker, “Five Practice-Changing Advances on the Horizon for Bladder Cancer,” B2B-Uro-oncology: GU Cancers Triad, Virtual, May 21, 2021.
2. Invited Speaker, Clinical Dilemmas in Management of NMIBC. “The Natural History of High Risk NMIBC: Novel Therapies versus Cystectomy?” Drug Development in NMIBC from Scientific, Regulatory, Clinician, and Patient Perspectives - A Johns Hopkins Greenberg Bladder Cancer Institute/ American Urological Association Translational Research Collaboration, Virtual March 4-6, 2021

3. Invited Speaker, Deintensification of Management of Low-Risk Non-Muscle-Invasive Bladder Cancer Symposium, “Optimizing Personalized Management of Non-muscle-Invasive Bladder Cancer” 2021 Genitourinary Cancers Symposium, Virtual, February 11-13, 2021
4. Visiting Professor, Society of Argentinian Urology, “BCG Refractory NMIBC”, July 2, 2020
5. Chair and Moderator, Confronting Obstacles in Treating Non-Muscle-Invasive and Upper Tract Urothelial Carcinoma, 2020 Genitourinary Cancer Symposium, ASCO, February 14, 2020
6. Invited Speaker, Congreso Sociedad Mexican de Urologia (SMU) 2019 “AUA Oncology Highlights”, Merida, Mexico, November 15-18, 2019
7. Invited Speaker, Congreso Sociedad Mexican de Urologia (SMU) 2019 “BCG for NMIBC”, Merida, Mexico, November 15-18, 2019
8. Invited Speaker, Congreso Sociedad Mexican de Urologia (SMU) 2019 “Prostate MRI is Here to Stay”, Merida, Mexico, November 15-18, 2019
9. Invited Speaker, Congreso Sociedad Mexican de Urologia (SMU) 2019 “Sarcopenia and Nutrition as Predictive Factors in Radical Cystectomy”, Merida, Mexico, November 15-18, 2019
10. Invited Speaker, Asociación Española de Urología (AEU) 2019, “Best of AUA: Immunotherapy”, Toledo, Spain, October 11, 2019
11. Invited Speaker, Confederación Americana de Urología (CAU) 2019, “Sarcopenia and Nutrition as Predictors of Radical Cystectomy Outcomes”, Buenos Aires, Argentina, October 3, 2019
12. Invited Speaker, British Association of Urology 2019 Annual Meeting, “Sarcopenia, nutrition, and other predictors of complications in bladder cancer surgery,” Glasgow, Scotland, June 25, 2019
13. Invited Speaker, Simposio Internacional “Avances en Urología 2019”, Sociedad Argentina de Urología, “Panel: Challenging Cases in Oncology” Buenos Aires, Argentina, April 12, 2019
14. Invited Speaker, Simposio Internacional “Avances en Urología 2019”, Sociedad Argentina de Urología, “Management of small renal masses” Buenos Aires, Argentina, April 12, 2019
15. Invited Speaker, Simposio Internacional “Avances en Urología 2019”, Sociedad Argentina de Urología, “Minimally invasive cystectomy: tips and tricks” Buenos Aires, Argentina, April 12, 2019
16. Invited Speaker, Simposio Internacional “Avances en Urología 2019”, Sociedad Argentina de Urología, “BCG in non-muscle invasive bladder cancer” Buenos Aires, Argentina, April 11, 2019
17. Invited Speaker, Simposio Internacional “Avances en Urología 2019”, Sociedad Argentina de Urología, “Active surveillance for prostate cancer” Buenos Aires, Argentina, April 11, 2019
18. Invited Speaker, XLIII Congreso Internacional del Colegio Mexicano de urología nacional, “Variant Histology in NMIBC,” Monterrey, MX, March 5, 2019
19. Invited Speaker, XLIII Congreso Internacional del Colegio Mexicano de urología nacional, “Advances in Upper Tract Urothelial Cancer,” Monterrey, MX, March 5, 2019
20. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Diagnosis and Treatment of NMIBC in 2018” Coquimbo, Chile, December 1, 2018
21. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Round Table: Urologic Oncology (case discussions)” Coquimbo, Chile, December 1, 2018
22. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Update on upper tract urothelial cancer” Coquimbo, Chile, December 1, 2018
23. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Current management of small renal masses” Coquimbo, Chile, November 30, 2018
24. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Active surveillance for prostate cancer” Coquimbo, Chile, November 30, 2018
25. Invited Speaker, 40th Congreso Chileno de Urología, Sociedad Chilena de Urología, “Cystectomy versus radiation/trimodality therapy for invasive bladder cancer” Coquimbo, Chile, November 29, 2018
26. Invited Speaker, Congreso Sociedad Mexicana de Urologia (SMU), “Highlights of the AUA: Oncology” Leon, Mexico, November 8, 2018
27. Invited Speaker, Confederación Americana de Urología, Prostate Cancer Course, “Update on Prostate Cancer Assessment; Practical Recommendations, Fusion or Non-fusion, Prostate Re-Biopsy,” Punta Cana, Dominican Republic, November 2, 2018
28. Invited Speaker, Confederación Americana de Urología, “AUCA lecture: The Management of High Risk NMIBC” Punta Cana, Dominican Republic, November 1, 2018
29. Invited Speaker, Confederación Americana de Urología, “BCG-refractory NMIBC” Punta Cana, Dominican

Republic, November 1, 2018

30. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Variant Histology in Bladder Cancer” Buenos Aires, Argentina, September 17, 2018
31. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Advancements in Upper Tract Urothelial Cancer” Buenos Aires, Argentina, September 17, 2018
32. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “AUA Guidelines: Localized Prostate Cancer” Buenos Aires, Argentina, September 16, 2018
33. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Active surveillance for prostate cancer” Buenos Aires, Argentina, September 16, 2018
34. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “AUA Guidelines: MIBC” Buenos Aires, Argentina, September 16, 2018
35. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Urinary diversion and metabolic derangements” Buenos Aires, Argentina, September 16, 2018
36. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Management of the small renal mass” Buenos Aires, Argentina, September 15, 2018
37. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Selection and timing of nephrectomy for advanced kidney cancer” Buenos Aires, Argentina, September 15, 2018
38. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “BCG Immunotherapy for bladder cancer” Buenos Aires, Argentina, September 15, 2018
39. Invited Speaker, Sociedad Argentina de Urologia (SAU) 2018 Argentina Lessons in Urology/SAU Congress, “Management of BCG Refractory Bladder Cancer” Buenos Aires, Argentina, September 15, 2018
40. Invited Speaker, LIII Congreso Curso Internacional de Urología, Sociedad Colombiana de Urología, “Advanced in the Management of Upper Tract Urothelial Cancer” Cartagena, Colombia, September 6, 2018
41. Invited Speaker, LIII Congreso Curso Internacional de Urología, Sociedad Colombiana de Urología, “Management of BCG Refractory Disease” Cartagena, Colombia, September 5, 2018
42. Invited Speaker, LIII Congreso Curso Internacional de Urología, Sociedad Colombiana de Urología, “Highlights of the AUA” Cartagena, Colombia, September 5, 2018
43. Invited Speaker, AUA Lessons in Urology Course, XXVII Congreso Peruano de Urologia, “Bladder Cancer Care Pathways” Lima, Peru, August 1-4, 2018
44. Invited Speaker, AUA Lessons in Urology Course, XXVII Congreso Peruano de Urologia, “Radiation after Prostatectomy” Lima, Peru, August 1-4, 2018
45. Invited Speaker, AUA Lessons in Urology Course, XXVII Congreso Peruano de Urologia, “Superficial Bladder Cancer Imaging & Cystoscopic Enhancements” Lima, Peru, August 1-4, 2018
46. Invited Speaker, AUA Lessons in Urology Course, XXVII Congreso Peruano de Urologia, “Staging and Risk Stratification of MIBC” Lima, Peru, August 1-4, 2018
47. Invited Speaker, AUA Lessons in Urology Course, XXVII Congreso Peruano de Urologia, “Metabolic Derangements that occur with diversions” Lima, Peru, August 1-4, 2018
48. Keynote Speaker, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Sydney, Australia, July 8-10, 2018
49. Invited Speaker, AUA Lessons in Urology Course, Sociedad Colombiana de Urologia (SCU), Medellin, Colombia, February 16-18, 2018. Invited Speaker, “Bladder Cancer: Care Pathways Impact Patient Outcomes,” 54 Congreso Argentino de Urologia, Sociedad Argentina de Urologia (SAU), Buenos Aires, Argentina, September 29, 2017.
50. Invited Speaker, “Bladder Cancer: Care Pathways Impact Patient Outcomes,” 54 Congreso Argentino de Urologia, Sociedad Argentina de Urologia (SAU), Buenos Aires, Argentina, September 29, 2017.
51. Invited Speaker, “Controversies in Urology: Transperineal Prostate Biopsy: Are We Moving the Needle?,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
52. Invited Speaker, “Bladder Cancer: Care Pathways Impact Patient Outcomes,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
53. Invited Speaker, “Superficial Bladder Cancer and Image-enhanced cystoscopy,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.

54. Invited Speaker, “Immunotherapy for Bladder Cancer,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
55. Invited Speaker, “AUA Guidelines: PSA And Prostate Cancer Screening,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
56. Invited Speaker, “AUA Guidelines: Radiation after prostatectomy,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
57. Invited Speaker, “AUA Guidelines: Castrate Resistant Prostate Cancer,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
58. Invited Speaker, “Focal Therapy for Prostate Cancer is the Future,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
59. Invited Speaker, “Do we Need Extended Node Dissections for Bladder and Renal Cancer?,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
60. Invited Speaker, “Renal and Bladder Cancer Case Discussion,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 28, 2017.
61. Invited Speaker, “Prostate Cancer Case Discussion,” Curso de Actualización en Urología, Sociedad Argentina de Urologia (SAU)/American Urological Association (AUA), Buenos Aires, Argentina, September 27, 2017.

National

1. Invited Speaker, “International Opportunities and Perspectives in Urologic Oncology”. SUO 2021. Orlando, FL December 2-4, 2021
2. Moderator, “Bladder Cancer I: Non-Muscle Invasive Bladder Cancer”. SUO 2021, Orlando, FL. December 2-4, 2021.
3. Moderator, “Bladder Cancer II: Upper Tract Urothelial Carcinoma”. SUO 2021, Orlando, FL. December 2-4, 2021.
4. Invited Speaker, FDA Virtual Public Workshop on Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC), “Patient-Focused Drug Development: Capturing High Quality Patient Experience Data” Virtual November 19, 2021.
5. Invited Keynote Speaker, Vanderbilt-Ingram Cancer Center Annual Scientific Retreat, “Translational Patient-Centered Outcomes Research in Bladder Cancer,” October 6, 2021.
6. Invited Visiting Professor, “Time Management Strategies to Combat Burnout and Improve Wellness” Weill Cornell, June 21, 2021.
7. Invited Speaker, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Virtual due to covid, June 4, 2021
8. Invited Visiting Professor, “Patient Engagement and Translational Patient-Centered Outcomes Research in Bladder Cancer” and “Time Management in a Digital World,” Loyola, May 7, 2021.
9. Invited Visiting Professor, “Time Management in a Digital World,” UT Health San Antonio, April 16, 2021.
10. Invited Lecture, SUO-YUO Symposium on Clinical Research and Clinical Trials, “Patient Centered Clinical Trial Development,” December 2, 2020 *virtual conference due to COVID-19
11. Invited Visiting Professor, University of Chicago, “PROs in Urology”, December 9th, 2020 *virtual conference due to COVID-19*
12. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Virtual due to covid, December 2020
13. Invited Keynote Speaker, “Success of PCORI in Urology”. *PKIDS Symposium* (Virtual) November 11, 2020; Philadelphia, PA.
14. Invited Visiting Professor, Johns Hopkins University, “PROs in Urology”, Baltimore, MD, October 8th, 2020 *virtual conference due to COVID-19*
15. Invited Visiting Professor, Georgetown University, “BCG Refractory NMIBC”, Washington DC, June 16, 2020

16. Invited Visiting Professor, Beth Israel Lahey Health, Boston, MA March 17-19, 2020 *virtual conference due to COVID-19
17. Invited Visiting Professor, University Hospitals, Cleveland, OH April 4-5, 2020 *cancelled due to COVID-19
18. Invited Speaker, “Ain’t Wastin’ No More Time: Tips for Time Management in a Digital World,” Society of Women in Urology, 9th Annual Clinical Mentoring Conference, New Orleans, LA, January 17, 2020
19. Invited Visiting Professor, “Translational Patient-Centered Outcomes Research in Bladder Cancer, UCLA, Los Angeles, CA May 21-22, 2019
20. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Austin, TX May 2019
21. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Austin, TX May 2018
22. Early Career Showcase Awardee, “Assessment of Blue Light Flexible Cystoscopy with Hexaminolevulinate on Patient Reported Outcomes: A prospective, multicenter, within-patient controlled study in detection of bladder cancer during surveillance,” AUA Early Career Investigator Showcase, May 2018.
23. Invited Plenary Speaker, “AUA White Papers: Optimizing Surgical Outcomes: Postoperative,” American Urological Association Annual Meeting, San Francisco, CA, May, 2018.
24. Invited Plenary Speaker, “How to Optimize Outcomes for Radical Cystectomy,” American Urological Association Annual Meeting, AUA/Brazilian Portuguese Urology Program, San Francisco, CA, May, 2018.
25. Invited Speaker, “Engaging Patients in Research: Researcher Perspective,” Bladder Cancer Advocacy Network, Bladder Cancer Think Tank, Charlotte, NC, August 4, 2017.
26. Invited Plenary Speaker, “Bladder Cancer Take Home Points”, American Urological Association Annual Meeting, Boston, MA, May 16, 2017.
27. Invited Speaker/Panelist, “Update on Gender in Urology Workforce,” Society of Academic Urology Annual Meeting, Boston, MA, May 11, 2017.
28. Invited Moderator, AUA – Podium Session “General & Epidemiological Trends & Socioeconomics: Quality Improvement & Patient Safety I.” American Urological Association Annual Meeting, Boston, MA, May 15, 2017.
29. Invited Moderator, “PROs in Clinical Practice,” Patient Reported Outcomes in Surgery Conference, Washington DC, November 17, 2016.
30. Invited Moderator, “Translating PROs into Clinical Practice,” Surgical Outcomes Club, Annual Scientific Session, Washington DC, October 16, 2016.
31. Invited Speaker, “Iceberg Session: The Hidden Challenges of Becoming a Successful HSR Researcher”, Ann Arbor Health Services Research Symposium, Ann Arbor, MI, September 19-20, 2016.
32. Invited Speaker, “Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer – Pro Cystectomy” Bladder Cancer Advocacy Network, 11th Annual Bladder Cancer Think Tank, Denver, Colorado, August 12-13, 2016.
33. Invited Discussant, General Surgery Health Services and Urology Research Forums, ACS Clinical Congress, 2016
34. Invited Faculty Presenter, “Robotic Radical Cystectomy: Getting Started and Tips and Tricks from the Experts” course, American Urological Association Annual Meeting, San Diego, CA, May 2016.
35. Invited Speaker, “Engaging Patient in Bladder Cancer Research Prioritization,” PCORI Annual Meeting, Arlington, VA, October 8, 2015.
36. Invited Speaker, Society of Urologic Oncology, Putting the “Patient” into Patient-Centered Outcomes Research Prioritization, Washington D.C., December 2015.
37. Invited Moderator, General & Epidemiological Trends & Socioeconomics Session, Southeast Section of the AUA Annual Meeting, Savannah, GA, March 19, 2015
38. Invited Guest Speaker, Doctor Radio, Sirius XM Radio (Channel 110) (topic: bladder cancer), October 7, 2015
39. Invited Faculty presenter, “Robotic Radical Cystectomy: Getting Started and Tips and Tricks from the Experts” course, American Urological Association Annual Meeting, San Diego, CA 2015
40. Invited Discussant, General Surgery Health Services Research Forum, ACS Clinical Congress, 2015
41. Invited Speaker, “The Influence of Patient Factors on Treatment Decision-Making.” Albert Institute Symposium on Bladder Cancer, Hartford, Connecticut, September 6, 2014
42. Invited Moderator, General & Epidemiological Trends & Socioeconomics Session, American Urological Association National Meeting, Orlando, FL, 2014
43. Invited Moderator, Urology and Reproductive Surgery I Session, ACS Clinical Congress, 2014
44. Invited Speaker, “Life after Cystectomy: the Role of Gender in Functional Outcomes.” Bladder Cancer Advocacy Network, 8th Annual Bladder Cancer Think Tank, Snowmass Village, Colorado, August 8, 2013.

45. Invited Moderator, Bladder Cancer: Invasive Session, AUA National Meeting, San Diego, CA, 2013
46. Invited Discussant, Urological Surgical Forum, ACS Clinical Congress, 2012

National

1. AUA Methods in Clinical Urology Research (MCURe) Workshop mentor, 2021
2. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” 2021
3. Invited Lecturer, Comprehensive Review of Urology, “Non-muscle invasive bladder cancer,” 2021
4. Invited Lecturer, AUA Core Curriculum, Adrenal, Section Chair, 2018—2021
5. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Virtual, 2020
6. Invited Lecturer, Comprehensive Review of Urology, “Non-muscle invasive bladder cancer,” 2020
7. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Austin, TX May 2019
8. Invited Lecturer, AUA Annual Board Review Course, “Muscle Invasive Bladder Cancer,” Austin, TX May 2018
9. Invited Course Faculty, “Robotic Radical Cystectomy: Getting Started and Tips and Tricks from the Experts,” American Urological Association Annual Meeting, San Diego, CA 2016
10. Invited Course Faculty, “Robotic Radical Cystectomy: Getting Started and Tips and Tricks from the Experts,” American Urological Association Annual Meeting, San Diego, CA 2015

Regional

1. Triangle Bladder Cancer Support Group, invited speaker, December 14, 2021
2. “Hematuria and Bladder Cancer Evaluation and Management.” WakeMed Internal Medicine Grand Rounds, invited speaker, March 24, 2015
3. “Navigating secondary data analysis and large datasets.” Charlotte Medical Center, invited speaker, August 1, 2014.
4. Men’s Prostate Health. Men’s Fellowship Breakfast, New Bethel Baptist Church, Rolesville, North Carolina, September 16, 2012
5. Women and Bladder Cancer. Triangle Bladder Cancer Network, Chapel Hill, NC, October 9, 2012

Attending on Clinical Service

- Urology Service attending (2012—present)

Graduate supervision or committees

- Junior Faculty Annual Review Committee for HPM, Angela Stover, PhD

Mentorship/Student Supervision

- T32 Cancer Care Quality Training Program (CCQTP), Mentor, 2020—present
- Surgical Outcomes Club, Zinner Fellowship Mentor
 - Lee Hugar, MD, University of Pittsburgh Urology Resident, 2017-2018
- UNC Urology Residency Mentor Program
 - Michael Emmerling, UNC Urology Resident, 2021—present
 - Christine Nikas, UNC Urology Resident, 2018—present
 - Pauline Filippou, UNC Urology Resident, 2015-2020
 - Sophie Spencer, UNC Urology Fellow, 2013-2019
- American Medical Women’s Association Mentor (Annual Mentorship Program for UNC)
 - Shannon Gillespie, 2016-2018
 - Hyun “Cindi” Lee, 2014-2016 (description from mentee below):
 - “Having Dr. Smith as my AMWA mentor has been a fruitful experience. She has set aside time from her busy schedule to counsel me every month, going over my goals for the semester and sharing with me her own experiences and strategies on accomplishing them. She’s always been very patient, understanding and supportive, and the mentorship experience has been both academically and personally rewarding. I cannot thank enough for having met an incredible role model whom I look up to and aspire to become.”

- Daniella DiNizo, 2012-2016 (description from mentee below):
 - “Dr. Smith has been amazing resource throughout medical school. She is compassionate and positive, but honest, which made it easy for me to turn to her for guidance not only on research design and manuscript drafts, but also on picking a specialty and life in medical school. She helped me develop plans for studying for the USMLEs and gave me great insight into how to be an effective learner and team member during my clinical rotations. I owe a lot of my success to her direction and guidance.”
- Residents (Clinical/Research Mentorship)
 - Katy Reines, UNC Urology Resident, 2020-present
 - Yousef Abu-Salha, UNC Urology Resident, 2020-present
 - Christine Nikas, UNC Urology Resident, 2019-present
 - Alysen Demzik, UNC Urology Resident, 2019-present
 - Kate Hacker Gessner, UNC Urology Resident and Fellow, 2016-present
 - Pauline Filippou, UNC Urology Resident, 2015-2021
 - Hannah McCloskey, UNC Urology Resident, 2019-2020
 - Case Wood, UNC Urology Resident, 2016-2019
 - Gopal Narang, UNC Urology Resident, 2016-2018
 - Brandon Garren, UNC Urology Resident, 2016-2017
 - Ben McCormick, UNC Urology Resident, 2016-2017
 - Jason Lomboy, UNC Urology Resident, 2015-2017
 - Sophie Spencer, former UNC Urology Resident, 2013-2017
 - Josip Vukina, former UNC Urology Resident, 2014-2016
 - Max McKibben, former UNC Urology Resident, 2014-2016
 - Abram McBride, former UNC Urology Resident, 2014-2016
 - David Johnson, former UNC Urology Resident, 2012-2016
 - Matt Macey, UNC Urology Resident, 2015
- Medical Students (Clinical/Research Mentorship)
 - Gabrielle Nortey, University of North Carolina Medical Student, 2021-present
 - Taylor Parisse, Campbell University Medical Student, 2019-present
 - Lucas Bouknight, University of North Carolina Medical Student, 2019-2021
 - Nathan Suskovic, University of North Carolina Medical Student, 2019-2021
 - Megan Gurjar, University of North Carolina Medical Student, 2019-2020
 - Judy Hamad, University of North Carolina Medical Student, 2019-2020
 - Charan Mohan, University of North Carolina Medical Student, 2018-2020
 - Cole Locklear, University of North Carolina Medical Student, 2015-2016
 - Emma Babb, University of North Carolina Medical Student, 2014-2016
 - Chris Koller, University of North Carolina Medical Student, 2014-2016
 - Stephen Proctor, University of North Carolina Medical Student, 2014-2015
 - Micah Whited, University of North Carolina Medical Student, 2013-2014
 - Megan Feng, Ohio State University Medical Student, 2011-2014
- Graduate Student Supervision
 - Gabrielle Nortey, CCQTP advisor, UNC, 2021-2022
 - Taylor Parisse, MPH thesis advisor, UNC Gillings School of Public Health, 2020-2021
 - Judy Hamad, MPH thesis advisor, UNC Gillings School of Public Health, 2019-2020
 - Nancy Wang, MPH thesis advisor, UNC Gillings School of Public Health, 2012-2014
 - Dan McMillan, MPH thesis advisor, UNC Gillings School of Public Health, 2012-2013
- Undergraduates
 - Mahima Reddy, 2016-2017, Pennsylvania Governor’s School for the Sciences Mentor
 - Amanda Pruthi, 2014-2015, research study evaluating readership in urology materials

GRANTS

Current

PCS-2019C3-9380

Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes 3/1/2019-2/23/2024
Patient-Centered Outcomes Research Institute \$8,500,000 (20% effort)

“CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer”

CISTO is a prospective observational cohort study of patients with non-muscle invasive bladder cancer (NMIBC) that have failed first-line BCG, and their caregivers. In this study, patient-reported outcomes and patient-centered clinical outcomes will be compared between patients undergoing radical cystectomy and those receiving bladder-sparing intravesical therapies for NMIBC. Additional aims include evaluating the heterogeneity of treatments received and corresponding patient/caregiver preferences as well as comparing the impact of treatment on caregivers.

Role: co-PI

1R01HS028455-01

Agency for Healthcare Research and Quality R01 9/1/2021 – 8/31/2024
\$500,000 (5% effort)

Development of a Shared Decision Making Support (SDM-S) Measure for Use with Team-based Care

Role: Co-investigator

This study develops patient-reported shared decision making (SDM) support (SDM-S) subscales to evaluate and compare the predictive validity of clinician-focused versus overall SDM-S subscales and evaluates patient acceptability of SDM-S subscales in real world primary and oncology care settings.

Merck-RTI

Patient Preferences in NMIBC 4/1/2021-3/31/2022
\$102,430 (15% effort)

This study is a cross-sectional observational cohort study in which we will characterize patient preferences using discrete choice experiment among those with non-muscle invasive bladder cancer for a variety of important health states defined below (low/high grade bladder cancer, newly diagnosed, recurrent and NMIBC that fails BCG).

Role: PI

G-89311

Genentech 1/1/2021-12/31/2023
\$749,994 (4% effort)

Identifying Opportunities to Pursue Equity When Implementing Virtual Visits in Oncology Care

The purpose of this mixed-methods project is to identify how oncology practices are considering equity as they design new virtual visit programs and determine how virtual visits in oncology hinder or enhance care access and quality among Black adults diagnosed with cancer.

Role: Co-I

Pending

Patient-Centered Outcomes Research Institute (PCORI)

ChemoRadiation Or Cystectomy for Urothelial Bladder Cancer Study 11/1/22-10/31/27 (submitted 1/22)
\$5,000,000 (20% effort)

In this prospective, cohort study, we will compare patient-reported and patient-centered clinical outcomes between patients undergoing radical cystectomy and those receiving bladder-sparing chemoradiation for muscle-invasive bladder cancer (MIBC). We will also characterize the heterogeneity of treatment effects for patients undergoing radical cystectomy and bladder-sparing chemoradiation and corresponding patient and provider preferences for MIBC.

Role: Co-PI

National Institutes of Health (NIDDK)

R01 9/1/22-8/31/27 (submitted 2/2022)
\$3,000,000 (20% effort)

Personalized Intervention to Reduce Cystoscopy Discomfort

In this multi-center pragmatic trial, we plan to compare patient-reported outcomes between patients undergoing evidence-based interventions to reduce cystoscopy discomfort, determine which interventions reduce cystoscopy discomfort for specific patient subgroups, and assess and address implementation challenges during the trial to inform future dissemination and implementation of study results.

Role: co-PI

Department of Defense
CDMRP

Submitted 9/2021
\$998,218 (15% effort)

A Theory-Based Longitudinal Examination of Outcomes of Caregivers and Patients with Bladder Cancer

This research will evaluate the longitudinal impact of caregiving in non-muscle invasive bladder cancer, a cancer which significantly increases caregiver burden, thereby informing the design and evaluation of a treatment decision aid to improve patient- and caregiver-associated outcomes in bladder cancer and other malignancies.

Role: Co-PI

National Institutes of Health (NCI) To be submitted 6/2022

R01 \$3,000,000 (20% effort; to be submitted 6/2022)

Systematic Translation of Patient-Prioritized Research into Urologic Cancer Care

This research will aim to incorporate patient priorities for research into national research agendas, identify clinical gaps in care, primary endpoints and known comparators for patient-prioritized research questions and conduct comparative effectiveness research to answer novel patient-centered research questions in urologic oncology.

Role: Co-PI

Completed

Mayo Clinic in Rochester

03/01/2020-02/28/2022

Sexual Function in Women Undergoing Radical Cystectomy

\$11,204 (0% effort)

There is an unmet need in providing preoperative information on changes in sexual function post-operatively in women. The reasons that the aforementioned data are either poor or do not exist are small sample size from single institution series, retrospective design and lack of standardized gender specific questionnaires. In addition, there is an assumption that the population at risk is not sexually active at baseline given older age and post-menopausal status.

Role: Site PI

Developmental Pilot Award

2/1/2021-1/31/2022

UNC Lineberger

\$50,000 (0% effort)

Defining the impact of telemedicine on shared decision-making surrounding treatment choices for black patients.

The purpose of this qualitative study is to describe the impact of telemedicine on the experience of SDM surrounding treatment choice for Black patients with localized prostate cancer, adapting the SDM model using an iterative, stakeholder-engaged process.

Role: Co-I

Bladder Cancer Advocacy Network

10/01/2020-09/30/2021

Patient Survey Network Award: Sponsored by Urogen Pharma Inc.

\$117,422 (10%)

Health-Related Quality of Life (HRQOL) outcomes in study TC-BC-12 in patients with LG IR NMIBC

The goal of this study is to evaluate longitudinal changes in five key health-related quality of life outcomes from baseline up to 12 months, determine demographic and clinical characteristics associated with these outcomes, and compare outcomes between specific subgroups (e.g. patients with newly diagnosed disease, patients with recurrent disease, and those who subsequently either had or did not have a recurrence).

Role: PI

Bladder Cancer Advocacy Network

2/1/2020-1/31/2021

Patient Survey Network Award: Sponsored by Urogen Pharma Inc.

\$165,000 (10% effort)

Patient and Provider Perception of Repeat Transurethral Resection of Bladder Tumor (TURBT)

This study is a mixed methods study which investigates the patient burden or perception of repeat TURBTs as it compares to provider perception among patients with NMIBC.

Role: PI

EAIN-00072

Promoting Implementation of Patient Engagement (PIPE)

8/1/2019-7/31/2020

Patient-Centered Outcomes Research Institute

\$50,000 (2.5% effort)

This award provides conference support to continue the benefits of the PEER in-person training program while also formalizing a process to unite PEER Scholars with research teams, integrate PEER Scholars into clinical trial groups/designers, and disseminate bladder cancer patient-centered outcomes research to patient/caregiver audiences.
Role: PI

NIH Loan Repayment Program 7/1/2012-7/30/2020
National Institute of Aging \$122,000 (0% effort)

A Patient-Centered mHealth Tool to Enhance Post-Cystectomy Care in the Elderly

This award is designed to recruit and retain highly qualified health professional into biomedical or biobehavioral research careers. For my work evaluating the geriatric bladder cancer population, I was awarded an initial 2-year term in 2012 and was successfully renewed for annual awards thereafter.

Role: PI

2UG1CA189823-06 8/1/2019-7/31/20
Cancer Care Delivery Research Pilot Award \$90,108 (1%)

Feasibility Testing of Patient Reported Outcomes-Informed Symptom Management System (PRISMS)

The objective of the proposed exploratory proof of concept study is to gather preliminary data to support a subsequent multi-site R01 proposal for wide efficacy testing of PRISMS (web-based self-management program) among cancer patients and caregivers at NCORP sites, as a CCDR study through the Alliance.

Bladder Cancer Advocacy Network 5/1/2019-4/30/2020
Patient Survey Network Award: Sponsored by Ferring Pharmaceuticals \$106,499 (10% effort)

Quality of Life in Bladder Cancer: A Cross-Sectional Study of the BCAN Patient Survey Network

This study is a cross-sectional observational cohort study in which we will infer the longitudinal impact of bladder cancer on patient quality of life (QOL) by characterizing QOL for different treatment trajectories at observed times since receipt of treatment.

Role: PI

R13HS026679 09/01/2018-08/31/2019
American Urological Association's QI Summit: Opioid Stewardship in Urology \$35,100 (0% effort)

The AUA convened a multi-stakeholder Quality Improvement Summit to address topics surrounding opioid stewardship, bringing together experts from urology, broader surgical specialties, anesthesia, pain management, addiction medicine, and several relevant public service organizations to discuss a variety of topics including: post-operative pain management strategies, physician-led interventions in opioid stewardship, policy and outreach work related to these topics, the identification and management of patients at high-risk for opioid related issues in the peri-operative period.

Role: PI

PCORI Engagement Award (PI: Angela Smith) 7/1/2017-6/30/2019
Knowledge Award PCORI EAIN-6148 \$249,000 (10% effort)

Patient Empowerment through Engagement Research Training in Bladder Cancer PCOR (PEER)

This award involves development of a bladder cancer research training module supplemented with existing training materials available through the PCORI-funded web-based portal (INSPIRE) and a workshop at a BCAN leadership conference. The effectiveness of this training tool (PEER –Patient Empowerment in Engagement Research) will be tested through patient engagement in identifying and refining a patient-centered research question and involvement in an existing PCOR project. Ultimately, trained patients will serve as mentors for future cohorts, creating a sustainable method for continued patient engagement in bladder cancer research.

Role: PI

1K08HS024134-01A1 (PI: Angela Smith) 4/1/2016 – 3/31/2019
AHRQ \$464,759 (75% effort)

Developing an Interactive, Patient-Centered mHealth Tool to Enhance Post-Cystectomy Care

The goal of this award is to support the PI in becoming an independently funded physician-scientist who is actively engaged in health information technology (HIT) interventions that improve the process and outcomes of care of surgical patients following discharge. Using radical cystectomy as a model, the proposed research seeks to develop and pilot test an electronic, internet-based mHealth tool that prospectively collects patient centered outcome data on key symptoms,

functional status, and medication adherence.

Role: PI

Academic Career Leadership Academy in Medicine (ACCLAIM) Leadership Award

8/1/2017-8/1/2018

\$18,750 (7.5% effort)

This award is awarded to participants interested in leadership opportunities to advance research. The ACCLAIM provides leadership and career development opportunities to junior faculty members, with an emphasis on those underrepresented in medicine.

R01CA174453 (supplement) (PI: Reeve and Chen)

9/21/2016 – 7/31/2017

PROMIS Validation in Prospective Population-based Prostate Cancer

\$150,000 (1% effort)

This supplement investigates (1) whether routine use of PROMIS and other patient-reported measures in clinical practice is feasible and valuable for clinical management of symptoms among Black and White prostate and bladder cancer patients; and (2) whether feasibility and perceived value differ by race.

Role: Supplement Lead, co-investigator

PCORI Engagement Award (PI: Angela Smith)

12/1/2014-12/1/2016

Knowledge Award 1089-BCAN

\$121,237 (5% effort)

Bladder Cancer Patient Survey Network for Research Prioritization

This knowledge award involves development of a survey network of bladder cancer patients by engaging patients and caregivers involved with Bladder Cancer Advocacy Network and conduct research prioritization activities. In this project, we aim to recruit users to participate in the Patient Survey Network, generate research questions, and prioritize research questions with the ultimate goal to create a sustainable method for conducting research prioritization with bladder cancer patients on an iterative and ongoing basis

Role: PI

University Cancer Research Fund (PI: Ron Chen)

8/1/2013-8/1/2015

Innovation Award

\$175,000 (5% effort)

Building and Characterizing the North Carolina Bladder Cancer Cohort: Defining Quality of Life and Potential Health Care Needs During Survivorship

Role: Co-investigator

KL2TR000084 (PI: Marshall Runge)

11/1/2012-7/1/2015

NIH/NCATS

\$2,090,864 (Direct) (75% effort)

UNC Clinical Translation Science Award-K12 Scholars Program (KL2)

Functional Assessment and p16 as Predictive Tools for Outcomes following Radical Cystectomy in the Elderly

75% effort/ 75% salary support

A national consortium with the goal of transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients.

Role: KL2 Scholar

North Carolina Cancer Hospital (PI: Angela Smith)

4/1/2014-3/30/2015

Endowment Fund Award

\$20,000 (5% effort)

Phone-Based Intervention for Reducing Readmissions

This quality improvement project implements a phone-based intervention at discrete time points post-discharge following radical cystectomy for bladder cancer. Specific questions address patient symptoms, including fatigue, dehydration, and depression, with the aim of identifying preventable causes of readmissions before they escalate.

Role: PI

University Research Council Grant (PI: Sutherland)

10/01/10-10/01/11 (5% effort)

Testing the CEVL (Computer Enhanced Visual Learning) Method for Urologic Procedures in Resident Learning

The goal of this study is to examine whether a computerized method of visual learning provides a consistent learning experience and is reproducible across institutions and individual surgeons in training.

Role: Co-PI

SERVICE

To Discipline

State Offices or Committees

- American Urological Association- Representative for Southeast Section for Journal of Urology editorial board, 2020—present
- Southeast Section, Associate Member, 2012—present
 - Abstract Reviewer, Southeast Section of AUA Annual Meeting, 2012—present
 - AUA Southeast Sectional Residents Committee Member, 2010—2011
- North Carolina Urological Association member, 2017—present
 - Board of Directors, 2017—2019

National Offices or Committees

- American Urological Association (AUA), Member, 2008—present
 - AUA Science and Quality Council, 2021-present
 - AUA Urology Care Foundation Bladder Health Committee, chair, 2019-present
 - AUA Assistant Secretary for Latin America/Caribbean, 2018—present
 - AUA Urology Care Foundation, Public Health Education council, member, 2017-present
 - Abstract Reviewer, AUA Annual Meeting, 2014—present
 - AUA, Quality Improvement & Patient Safety Committee, member, 2017-2020
 - AUA Urology Care Foundation Bladder Health Committee, member, 2015-2017, chair-elect, 2017-2019
 - AUA Urology Care Foundation Non-Muscle and Muscle Invasive Bladder Cancer Expert Panel, member, 2016-2017
 - AUA Urology Care Foundation Expert Pain Committee, chair, 2016-2017
- American College of Surgeons (ACS), Abstract Reviewer, ACS Clinical Congress, 2014 – Present
 - Associate Fellow, 2012—present
- Society of Women in Urology, 2012—present
 - Board of Directors, 2019—present
- Surgical Outcomes Club, 2012—present
 - Board of Directors, 2015—2018
 - Treasurer, 2016—2018
 - Moderator, “Translating Patient Reported Outcomes from Surgical Research to Clinical Care,” Surgical Outcomes Club Annual Meeting, 2016
- Society of Medical Decision Making, member 2012—2013
- Society of Urologic Oncology (SUO), 2014—present
 - SUO Members Committee, 2021—present
 - SUO Scientific Program Planning Committee, 2021—present
 - SUO Survey Committee, 2021—present
 - SUO Women in Urologic Oncology, 2020—present (founder, board member)
 - Abstract Reviewer SUO Annual Conference, 2015—present
 - SUO Young Urologic Oncologists Board Chair, 2019—2020

- SUO Young Urologic Oncologists Board Member, 2015—2020
- SUO Planning Committee for Health Services Research, 2015—2016
- Association of Women Surgeons, Outreach Committee, 2018-present
- Bladder Cancer Advocacy Network, member, 2017—present
 - Scientific Advisory Board member, 2017-present
 - Think Tank Steering Committee, 2018, 2019
- Patient-Centered Outcomes Research Institute (PCORI)
 - PCORI Ambassador, 2016-present
 - PCORI Advisory Panel Member on the Assessment of Prevention, Diagnosis, and Treatment Options, Washington, D.C., 2014-2017
- National Cancer Institute, SEER Bladder Workgroup member, 2015-present
- Alliance Cooperative Group, Symptom Committee member, 2014-present
- Industry Advisory Boards
 - Merck, 2020-2023
 - Ambu, 2021-2022
 - Fergene, 2020-2021
 - Urogen, 2019-2021
 - Photocure, 2014-2019

International Offices or Committees

- American Urological Association Assistant Secretary for Latin America/Caribbean/Spain 2018-2022
- International Bladder Cancer Group (IBCG), Bladder Cancer Center for Population Health and Health Services Research, committee member, 2021-present

Editorial Appointments

- Editorial Board Member, *Urologic Oncology: Seminars and Original Investigations*, 2021—present
- Associate Editor, *Bladder Cancer Journal*, 2021—present
- Editorial Board Member, *The Journal of Urology*, Southeastern Section Representative, 2020—present
- Assistant Editor of Online Content, *Journal of Urology*, 2016—present
- Editorial Board Member, *Journal of Urology and Research*, 2014—present
- Assistant Editor, *Bladder Cancer Journal*, 2016—2021
- Social Media Editor, *Bladder Cancer Journal*, 2015-2016
- Ad Hoc Editorial Review Activities
 - *Cancer*
 - *Journal of Urology (Awarded Best Reviewer in 2013 and 2014)*
 - *Urology*
 - *JAMA*
 - *JAMA Surgery*
 - *Journal of Surgical Oncology*
 - *Journal of the National Comprehensive Cancer Network*
 - *Urologic Oncology: Seminars and Original Investigations*
 - *International Journal of Urology*
 - *Journal of Clinical Oncology*
 - *Case Reports in Medicine*
 - *Prostate Cancer and Prostatic Diseases*

Review Panels

- UNC Protocol Review Committee, 2021—present
- BCAN Clinical Young Investigator Award, Review Panel Chair, 2019—present
- Patient-Centered Outcomes Research Institute- Translation Center, Reviewer, 2017—2018

Institutional (UNC-CH) Committees

- Faculty Affairs and Leadership Development Liaison, Urology, 2021—present
- SOM Committee to Review Appointments and Promotions to Associate Professor 2021—present
- Department of Surgery Chair Search Committee, member, 2021—present
- UNC PRO Core internal advisory board, 2019—present
- Committee Chair for Integration of ePROs into UNC Healthcare system, 2017—present
- 5-year chair review, Dr. Melina Kibbe, Department of Surgery, 2021
- Opioid Action Plan Committee, urology co-lead, 2017—2020
- Steering Committee Member, Hillsborough Medical Office Building, 2014—2019
- Director of Student & Resident Research, UNC Department of Urology, 2014—2019
- Survivorship Care Plan, GU Team Leader, 2014—2019
- Whitehead Medical Society VP of Educational Development, 2004—2005, 2006—2007
- Honor Court Board Member, University of North Carolina, School of Medicine, 2004—2007

Institutional Administrative Activities (division, clinic, section, or team)

- Well-being Liaison, Department of Urology, 2021—present
- Vice Chair for Academic Affairs, Department of Urology, 2020—present
- Director of Urologic Oncology, Co-Director of Genitourinary Oncology, 2019—present
- Director of Resident and Student Research, 2014—2019

Leadership/Career Development Training

- Center for Faculty Excellence Leadership Fundamentals Program, 2018-2019
- UNC ACCLAIM Leadership Development Program, 2017-2018
- Association of American Medical Colleges Early Career Women Faculty Professional Development Seminar, 2016
- UNC Practice Network Developing Physician Leaders Program, 2015-2016
- Early Career Investigators Workshop, AUA 2015-2016
- UNC ACCLAIM Leadership Development Workshop for Health Professionals, 2015

RESEARCH STATEMENT

My area of expertise in clinical research focuses on surgical outcomes, patient engagement, comparative effectiveness research, and patient-centered improvement in quality of care. My research foundation began with didactic coursework in the UNC School of Public Health, where I received a degree in biostatistics and hands-on experience as a statistical consultant for the Biometric Consulting Laboratory (BCL) under the mentorship of Dr. Gary Koch, co-founder of Quintiles (now IQVIA). As a urologic oncologist, I quickly developed a passionate interest in bladder cancer, an area in need of substantial quality improvement. The magnitude of this problem was underscored by my retrospective analyses, in which I found that nearly half of patients undergoing bladder cancer surgery were readmitted to the hospital within 90 days, and an even larger proportion experienced complications. Faced with this sobering reality, I was inspired by the belief that I, as a surgeon, could contribute to the development of innovative solutions to address the fundamental challenges of complex surgical care in the large and growing elderly population.

With funding from the UNC KL2 program, I conducted a prospective cohort study to examine the impact of functional status on cystectomy outcomes of bladder cancer patients. Through my KL2 award, I had 75% protected time to conduct my research and complete my Masters of Science in Clinical Research in Epidemiology at UNC. I presented my research at numerous national meetings and was invited as a guest speak about gaps in clinical outcomes research at several national meetings including the Patient-Centered Outcomes Research Institute (PCORI) and the Bladder Cancer Advocacy Network (BCAN) Think Tank. During this period, I also served as a member of the PCORI Advisory Panel

(selected as 1 of 10 members among ~5,000 applicants), which strengthened my understanding of patient-centered outcomes research and its relevance to my research goals. These complementary activities strengthened my long-term commitment to a career in which I develop and test innovative, patient-centered strategies to address potentially serious problems that cancer patients undergoing surgery experience following discharge. This led to the successful funding of an AHRQ K08 career development award in which I developed and evaluated the effectiveness of an innovative mHealth strategy that can rapidly identify and appropriately address potentially serious problems experienced post-discharge by bladder cancer patients undergoing surgery. For this research, I was awarded the UNC Junior Faculty Development Award, Jefferson-Pilot Fellowship in Academic Medicine Award, UNC Lineberger Clinical Fellows Award for Research Excellence, the NIH Loan Repayment Program, and a one-year research fellowship from the national Surgical Outcomes Club.

At this point, I transitioned to becoming a successful independent researcher by expanding my research to combine patient-reported outcomes (PROs) with comparative effectiveness research (CER) and patient engagement through interdisciplinary team science. I was awarded four successive PCORI Engagement Awards, in which I incrementally built, from the ground up, an international patient engagement platform for bladder cancer. I disseminated this work through several publications and invited speaking engagements, which served as an example for other researchers in both oncology and non-oncology fields. My work led to the successful funding of an \$8.5 million PCORI Large Pragmatic Trial (for which I serve as PI) which compares medical treatment to bladder removal for patients with recurrent non-muscle invasive bladder cancer, the top-ranked priority among >1,000 bladder cancer patients. I also serve as either the PI or co-investigator on numerous additional patient-centered grants that evaluate patient preferences, quality of life, shared decision-making, and equity in clinical cancer care. Each project is comprised of an interdisciplinary team, which complements and strengthens the research design and successful dissemination of results.

Despite hardships associated with the pandemic as noted in the COVID-19 Impact Statement below, I have remained productive, submitting 2 NIH R01 applications, a \$5 million PCORI application, and a DOD grant to compare interventions to reduce discomfort during cystoscopy, compare treatments for patients with invasive bladder cancer and evaluate the impact of bladder cancer on caregivers, all pending review – and reflecting co-investigators in other disciplines (e.g. School of Nursing, Health Policy and Management, Epidemiology, and Biostatistics). My innovative work in the areas of PROs, patient engagement, and comparative effectiveness research has been internationally recognized through numerous invited speaking engagements as well as awards. National awards include the American Urological Association Gold Cystoscope Award (the AUA's most prestigious award for mid-career urologists), Society of Urologic Oncology Young Investigator Award, American Urologic Association Young Urologist of the Year, and the Best of BCAN Award. Recent institutional awards include the prestigious UNC Hettleman Prize for Artistic & Scholarly Achievement and the Yang Family Biomedical Scholars Award. In summary, I have been privileged to conduct meaningful interdisciplinary clinical research that improves the quality of care and outcomes of patients with bladder cancer, and look forward to continuing my work by 1) promoting patient engagement in research 2) incorporating patient-reported outcomes in clinically relevant comparative effectiveness research and 3) developing and evaluating the effectiveness of innovative mHealth strategies that improve the quality of care among surgical patients.

TEACHING STATEMENT

While research and patient care are certainly important components of my role as an Associate Professor, I also strive to be an effective educator to urology residents, medical students, and junior faculty both from UNC and other institutions. My interest in education began as a chief resident when I overhauled the Urology Core Curriculum, coordinated pathology conferences and added multi-disciplinary lecturers to enrich the overall education of residents and faculty. Many of these changes persist and have been continually improved to further learning experiences. I also instituted a preoperative conference led by the chief resident each Friday, during which junior residents discuss the operative cases for the next week, develop operative plans and receive critiques and suggestions from the chief resident. This conference is now termed "Indications Conference" and is attended by faculty and residents.

My teaching responsibilities have continued as a faculty member at UNC, where I instruct both residents, medical students, and fellows in the clinic and operating room throughout the year. My most valuable educational role involves clinical research mentorship. I was appointed the inaugural Director of Resident and Student Research within the Department of Urology from 2014-2019. Since that time, I developed a curriculum of research activities and mentorship

for trainees that integrate with their clinical experience. Each trainee is matched with a research mentor according to his or her interests and career aspirations. I also individually met with each resident to augment professional development, evaluating their curriculum vitae and developing a strategic research plan to develop their career. I also provided lectures to highlight health services research, statistical methodology, and additional professional development resources. I stepped down from this role to become Director of Urologic Oncology in 2019, but I continue to be actively involved in resident and student education and seek active feedback from my learners in order to perpetually improve my teaching style. I have continued to participate in national education symposia for clinical education and research. For example, I have served as the clinical lecturer for muscle invasive bladder cancer for the annual American Urological Association Board Review Course since 2018. I have also participated in numerous research education courses such as the AUA Methods in Clinical Urology Research (MCURe) Workshop and Society of Urologic Oncology Clinical Trials Course. As a result of my teaching – both locally and nationally – my overall goal is to develop independent and thoughtful trainees with excellent clinical, research and operative abilities.

DIVERSITY, EQUITY, AND INCLUSION STATEMENT

Supporting diversity in education & research. I support DEI in education and research by providing mentorship experiences to undergraduate and medical students, residents and junior faculty. I have a strong record of supporting and training female urologists including 6 women in the past 7 years (three of whom are also underrepresented minorities). I have made a significant effort to engage undergraduate students (two underrepresented minorities) and numerous medical students (of whom several have been underrepresented minorities) – and introduce them to the field of urology. My efforts have been largely successful. Prior to joining the UNC urology faculty, our program had only trained 4 women in all of its history (myself included). After I was hired, we have since trained 10 women in urology. I have continued to actively pursue opportunities to promote DEI through mentorship. As an example, I am the current research mentor for a URM female medical student in the Holderness Fellowship and Clinician Leadership QI Safety Program. I have also served as a mock reviewer for the PROMISE Study (Peer group Research on Mentoring Scientists underrepresented in biomedical research) and also hosted several students in the Maricio Castillo, MD Diversity and Inclusion Scholars Program to participate/train in my urology clinic. I have also completed workshops on diversity, equity and inclusion (DEI) at the university, including unconscious bias training. Finally, my clinical research includes diversity, equity and inclusion – evaluating diversity in research engagement, and disparities in urologic cancer care, particularly as they relate to patient-reported outcomes and telemedicine.

Supporting diversity on a national level. I also champion diversity, equity and inclusion through my leadership position with the American Urological Association as their inaugural Assistant Secretary. These efforts have provided me a global platform for DEI, given my role in creating educational opportunities in Latin America, the Caribbean, Europe and beyond. I have accomplished this in many ways since beginning my position in 2018– 1) I have engaged with urologists and trainees in over 10 countries to better understand educational needs and provide clinical resources to address them; 2) I have held symposia for women urologists and trainees in several countries, which led to new societies (e.g. Colombia, Brazil, Mexico) to strengthen the visibility of women in these countries; 3) I have intentionally selected women and underrepresented minorities to serve as speakers, panelists, moderators and organizers for global meetings, significantly increasing speaker diversity within our national organization; and 4) I have created a global women leaders of urology group that has continued to grow since 2019 with over 25 countries represented. These efforts have been complemented by my participation on the Society of Women in Urology Board, in which I created a speaker’s database which can be requested by societies and organizations who wish to actively improve diversity in their programmatic meetings. I have engaged with the R. Frank Jones Urological Society (a society for Black urologists) to replicate this database within their organization, to achieve a similar mission. I also co-founded the Women in Urologic Oncology group in 2017, advocating for official recognition and funding from the Society of Urologic Oncology in 2020, for which I now serve on the board of directors. For these efforts, I was awarded the Ambrose Reed Award by the Southeast Section of the AUA in 2021 to recognize pioneers in the field of health policy and diversity, equity, and inclusion.

SERVICE AND ENGAGEMENT STATEMENT

I have an exceptionally strong track record of professional service and engagement that contributes to the service mission of the UNC School of Medicine, at an institutional, national and international level. Departmentally, I have served as the Director of Resident and Student Research and now serve as Vice Chair of Academic Affairs, Director of Urologic Oncology, Wellness Liaison, and Faculty Affairs and Leadership Development Liaison. Institutionally, I serve on the

SOM Committee to Review Appointments and Promotions to Associate Professor, the UNC PRO Core Internal Advisory Board, Committee Chair for Integration of ePROs in the UNC Healthcare System, among others. Nationally, I have been actively involved in many leadership positions in national organizations related to my discipline, including the American Urological Association (AUA), Society of Women in Urology, Surgical Outcomes Club, and Society of Urologic Oncology (among others). For the AUA, I have been selected to lead in numerous ways –chair of the AUA Urology Care Foundation Bladder Health Committee, the AUA Quality Improvement and Patient Safety Committee, and most recently the inaugural AUA Assistant Secretary for Latin America/Caribbean, a significant global role that involves programmatic organization of >15 countries and program planning for the annual AUA meeting, which hosts 16,000 attendees from over 100 countries. I also currently serve on the Board of Directors for the Society of Women in Urology and previously served on the board for the national Surgical Outcomes Club. I have been actively involved in the Society of Urologic Oncology, where I served as chair of the SUO Young Urologic Oncologists Board, founded the SUO Women in Urologic Oncology group (for which I serve on the board), and was elected by nomination/vote to the SUO Members Committee. I have received numerous awards, reflecting my contributions, most recently the AUA Gold Cystoscope Award (the AUA’s highest honor), AUA Ambrose-Reed Award, Yang Family Biomedical Scholars Award, UNC Hettleman Prize for Artistic & Scholarly Achievement, AUA Young Urologist of the Year, and Society of Urologic Oncology Young Investigator Award. I also engage in the patient community and am actively involved in the Bladder Cancer Advocacy Network, both locally and nationally, participating in a variety of research, clinical, policy, and advocacy activities (including the annual Walk for Bladder Cancer) – for which I was a keynote speaker in 2018 and awarded the Best of BCAN Award in 2019. Through these and other activities, my contributions have allowed me to proudly uphold UNC’s professional mission to improve the health, function, and wellbeing of people across North Carolina and beyond through excellence in patient care, education, research, and innovation.

COVID-19 PANDEMIC RELATED ACTIVITY/IMPACT

During the COVID-19 pandemic, I served several roles (in addition to my current responsibilities). These included assisting with telemedicine setup for our department, organizing oncology activities in the midst of covid (as director of urologic oncology), and leading departmental communications, such as daily updates, reminders, and other information (curating the large volume of information during this challenging time). As I am a cancer surgeon, my clinical volume did not decrease – although I was unexpectedly responsible for two children under 6 years at home, while continuing to work full time. Despite these challenges, I was able to maintain a productive research program, maintain my clinical activity (exceeding my RVU targets) and provide lectures (virtually) both nationally and internationally.